QUARTERLY REPORT

Q2 2020 — Quarterly report

Q2 2020PDF · 72 pages587 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 	10-Q
(Mark One)
☒ 	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the Quarterly Period Ended 	June 30, 2020
OR
☐ 	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934
For the transition period from 	to
Commission file number: 	001-16751
ANTHEM, INC.
(Exact name of registrant as specified in its charter)
Indiana 	35-2145715
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
220 Virginia Avenue
Indianapolis, 	Indiana 	46204
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (800) 	331-1476
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading symbol(s) 	Name of each exchange on which registered
Common Stock, $0.01 par value 	ANTM 	New York Stock Exchange
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the
past 90 days. 	Yes 	☒ 	No 	☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). 	Yes 	☒ 	No 	☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging
growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2
of the Exchange Act:
Large accelerated filer
☒
Accelerated filer 	☐
Non-accelerated filer
☐
Smaller reporting company 	☐
Emerging growth company 	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 	☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 	Yes 	☐ 	No 	☒
As of July 22, 2020, 	251,506,458 	shares of the Registrant’s Common Stock were outstanding.

-- 1 of 72 --

Anthem, Inc.
Quarterly Report on Form 10-Q
For the Period Ended 	June 30, 2020
Table of Contents
Page
PART I. FINANCIAL INFORMATION
ITEM 1. 	FINANCIAL STATEMENTS
Consolidated Balance Sheets as of June 30, 2020 (Unaudited) and December 31, 2019 	2
Consolidated Statements of Income (Unaudited) for the Three and Six Months Ended June 30, 2020 and 2019 	3
Consolidated Statements of Comprehensive Income (Unaudited) for the Three and Six Months Ended June 30, 2020 and 2019 	4
Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2020 and 2019 	5
Consolidated Statements of Shareholders’ Equity (Unaudited) for the Six Months Ended June 30, 2020 and 2019 	6
Notes to Consolidated Financial Statements (Unaudited) 	8
ITEM 2. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 	42
ITEM 3. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 	61
ITEM 4. 	CONTROLS AND PROCEDURES 	61
PART II. OTHER INFORMATION
ITEM 1. 	LEGAL PROCEEDINGS 	61
ITEM 1A. 	RISK FACTORS 	61
ITEM 2. 	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS 	62
ITEM 3. 	DEFAULTS UPON SENIOR SECURITIES 	62
ITEM 4. 	MINE SAFETY DISCLOSURES 	62
ITEM 5. 	OTHER INFORMATION 	62
ITEM 6. 	EXHIBITS 	63
SIGNATURES 	64
-1-

-- 2 of 72 --

PART I. FINANCIAL INFORMATION
ITEM 1. 	FINANCIAL STATEMENTS
Anthem, Inc.
Consolidated Balance Sheets
June 30,
2020
December 31,
2019
(In millions, except share data) 	(Unaudited)
Assets
Current assets:
Cash and cash equivalents 	$ 	6,028 	$ 	4,937
Fixed maturity securities (amortized cost of $21,358 and $19,021; allowance for credit losses of $24 and $0) 	22,018 	19,676
Equity securities 	3,470 	1,009
Premium receivables 	5,456 	5,014
Self-funded receivables 	2,460 	2,570
Other receivables 	3,072 	2,807
Other current assets 	4,260 	3,020
Total current assets 	46,764 	39,033
Long-term investments:
Fixed maturity securities (amortized cost of $491 and $487;
allowance for credit losses of $0 and $0) 	520 	505
Other invested assets 	4,097 	4,258
Property and equipment, net 	3,427 	3,133
Goodwill 	21,641 	20,500
Other intangible assets 	9,577 	8,674
Other noncurrent assets 	1,950 	1,350
Total assets 	$ 	87,976 	$ 	77,453
Liabilities and shareholders’ equity
Liabilities
Current liabilities:
Medical claims payable 	$ 	9,878 	$ 	8,842
Other policyholder liabilities 	3,586 	3,050
Unearned income 	946 	1,017
Accounts payable and accrued expenses 	5,257 	4,198
Short-term borrowings 	— 	700
Current portion of long-term debt 	1,603 	1,598
Other current liabilities 	7,252 	4,127
Total current liabilities 	28,522 	23,532
Long-term debt, less current portion 	19,873 	17,787
Reserves for future policy benefits 	776 	759
Deferred tax liabilities, net 	2,497 	2,227
Other noncurrent liabilities 	1,853 	1,420
Total liabilities 	53,521 	45,725
Commitments and contingencies – Note 11
Shareholders’ equity
Preferred stock, without par value, shares authorized – 100,000,000; shares issued and outstanding – none 	— 	—
Common stock, par value $0.01, shares authorized – 900,000,000; shares issued and outstanding –
252,122,363 and 252,922,161 	3 	3
Additional paid-in capital 	9,360 	9,448
Retained earnings 	25,346 	22,573
Accumulated other comprehensive loss 	(254) 	(296)
Total shareholders’ equity 	34,455 	31,728
Total liabilities and shareholders’ equity 	$ 	87,976 	$ 	77,453

-- 3 of 72 --

See accompanying notes.
-2-

-- 4 of 72 --

Anthem, Inc.
Consolidated Statements of Income
(Unaudited)
Three Months Ended
June 30
Six Months Ended
June 30
(In millions, except per share data) 	2020 	2019 	2020 	2019
Revenues
Premiums 	$ 	25,092 	$ 	23,501 	$ 	50,609 	$ 	46,344
Product revenue 	2,543 	144 	4,887 	144
Administrative fees and other revenue 	1,543 	1,532 	3,130 	3,077
Total operating revenue 	29,178 	25,177 	58,626 	49,565
Net investment income 	57 	285 	311 	495
Net realized gains (losses) on financial instruments 	18 	11 	(6) 	89
Impairment recoveries (losses) on investments:
Total impairment recoveries (losses) on investments 	6 	(9) 	(95) 	(22)
Portion of impairment losses recognized in other comprehensive income 	5 	2 	49 	5
Impairment recoveries (losses) recognized in income 	11 	(7) 	(46) 	(17)
Total revenues 	29,264 	25,466 	58,885 	50,132
Expenses
Benefit expense 	19,547 	20,368 	41,036 	39,650
Cost of products sold 	2,225 	98 	4,209 	98
Selling, general and administrative expense 	4,046 	3,278 	7,827 	6,444
Interest expense 	201 	184 	395 	371
Amortization of other intangible assets 	93 	85 	176 	172
Loss (gain) on extinguishment of debt 	3 	— 	4 	(1)
Total expenses 	26,115 	24,013 	53,647 	46,734
Income before income tax expense 	3,149 	1,453 	5,238 	3,398
Income tax expense 	873 	314 	1,439 	708
Net income 	$ 	2,276 	$ 	1,139 	$ 	3,799 	$ 	2,690
Net income per share
Basic 	$ 	9.02 	$ 	4.44 	$ 	15.06 	$ 	10.47
Diluted 	$ 	8.91 	$ 	4.36 	$ 	14.85 	$ 	10.28
Dividends per share 	$ 	0.95 	$ 	0.80 	$ 	1.90 	$ 	1.60
See accompanying notes.
-3-

-- 5 of 72 --

Anthem, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
June 30
Six Months Ended
June 30
(In millions) 	2020 	2019 	2020 	2019
Net income 	$ 	2,276 	$ 	1,139 	$ 	3,799 	$ 	2,690
Other comprehensive income, net of tax:
Change in net unrealized losses/gains on investments 	730 	238 	41 	595
Change in non-credit component of impairment losses on investments 	10 	(1) 	(22) 	(1)
Change in net unrealized gains/losses on cash flow hedges 	3 	— 	6 	3
Change in net periodic pension and postretirement costs 	10 	3 	17 	6
Foreign currency translation adjustments 	1 	— 	— 	—
Other comprehensive income 	754 	240 	42 	603
Total comprehensive income 	$ 	3,030 	$ 	1,379 	$ 	3,841 	$ 	3,293
See accompanying notes.
-4-

-- 6 of 72 --

Anthem, Inc.
Consolidated Statements of Cash Flows
(Unaudited)
Six Months Ended
June 30
(In millions) 	2020 	2019
Operating activities
Net income 	$ 	3,799 	$ 	2,690
Adjustments to reconcile net income to net cash provided by operating activities:
Net realized losses (gains) on financial instruments 	6 	(89)
Depreciation and amortization 	556 	586
Deferred income taxes 	60 	79
Share-based compensation 	134 	140
Changes in operating assets and liabilities:
Receivables, net 	(313) 	(589)
Other invested assets 	24 	(28)
Other assets 	(486) 	(258)
Policy liabilities 	1,024 	1,251
Unearned income 	(110) 	(2)
Accounts payable and other liabilities 	1,868 	(383)
Income taxes 	1,313 	(286)
Other, net 	150 	(44)
Net cash provided by operating activities 	8,025 	3,067
Investing activities
Purchases of investments 	(11,135) 	(11,113)
Proceeds from sale of investments 	4,724 	8,835
Maturities, calls and redemptions from investments 	1,836 	894
Purchases of subsidiaries, net of cash acquired 	(1,906) 	—
Purchases of property and equipment 	(437) 	(455)
Other, net 	(800) 	22
Net cash used in investing activities 	(7,718) 	(1,817)
Financing activities
Net (repayments of) proceeds from commercial paper borrowings 	(400) 	203
Proceeds from long-term borrowings 	2,484 	—
Repayments of long-term borrowings 	(155) 	(73)
Proceeds from short-term borrowings 	820 	4,805
Repayments of short-term borrowings 	(1,520) 	(4,940)
Repurchase and retirement of common stock 	(584) 	(752)
Cash dividends 	(482) 	(412)
Proceeds from issuance of common stock under employee stock plans 	92 	100
Taxes paid through withholding of common stock under employee stock plans 	(111) 	(80)
Other, net 	640 	43
Net cash provided by (used in) financing activities 	784 	(1,106)
Change in cash and cash equivalents 	1,091 	144
Cash and cash equivalents at beginning of period 	4,937 	3,934
Cash and cash equivalents at end of period 	$ 	6,028 	$ 	4,078

-- 7 of 72 --

See accompanying notes.
-5-

-- 8 of 72 --

Anthem, Inc.
Consolidated Statements of Shareholders’ Equity
(Unaudited)
Six Months Ended June 30, 2020
Common Stock Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Total
Shareholders’
Equity	(In millions)
Number of
Shares
Par
Value
December 31, 2019 (audited) 	252.9 	$ 	3 	$ 	9,448 	$ 	22,573 	$ 	(296) 	$ 	31,728
Adoption of Accounting Standards Update No.
2016-13 (Note 2) 	— 	— 	— 	(35) 	— 	(35)
January 1, 2020 	252.9 	3 	9,448 	22,538 	(296) 	31,693
Net income 	— 	— 	— 	1,523 	— 	1,523
Other comprehensive loss 	— 	— 	— 	— 	(712) 	(712)
Repurchase and retirement of common stock 	(1.9) 	— 	(71) 	(458) 	— 	(529)
Dividends and dividend equivalents 	— 	— 	— 	(243) 	— 	(243)
Issuance of common stock under employee stock
plans, net of related tax benefits 	1.0 	— 	3 	— 	— 	3
Convertible debenture repurchases and
conversions 	— 	— 	(42) 	— 	— 	(42)
March 31, 2020 	252.0 	3 	9,338 	23,360 	(1,008) 	31,693
Net income 	— 	— 	— 	2,276 	— 	2,276
Other comprehensive income 	— 	— 	— 	— 	754 	754
Repurchase and retirement of common stock 	(0.2) 	— 	(9) 	(46) 	— 	(55)
Dividends and dividend equivalents 	— 	— 	— 	(244) 	— 	(244)
Issuance of common stock under employee stock
plans, net of related tax benefits 	0.3 	— 	113 	— 	— 	113
Convertible debenture repurchases and
conversions 	— 	— 	(82) 	— 	— 	(82)
June 30, 2020 	252.1 	$ 	3 	$ 	9,360 	$ 	25,346 	$ 	(254) 	$ 	34,455
See accompanying notes.
-6-

-- 9 of 72 --

Anthem, Inc.
Consolidated Statements of Shareholders’ Equity (continued)
(Unaudited)
Six Months Ended June 30, 2019
Common Stock Additional
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Total
Shareholders’
Equity	(In millions)
Number of
Shares
Par
Value
December 31, 2018 (audited) 	257.4 	$ 	3 	$ 	9,536 	$ 	19,988 	$ 	(986) 	$ 	28,541
Adoption of Accounting Standards Update No.
2016-02 (Note 2) 	— 	— 	— 	26 	— 	26
January 1, 2019 	257.4 	3 	9,536 	20,014 	(986) 	28,567
Net income 	— 	— 	— 	1,551 	— 	1,551
Other comprehensive income 	— 	— 	— 	— 	363 	363
Repurchase and retirement of common stock 	(1.1) 	— 	(71) 	(223) 	— 	(294)
Dividends and dividend equivalents 	— 	— 	— 	(206) 	— 	(206)
Issuance of common stock under employee stock
plans, net of related tax benefits 	1.1 	— 	69 	— 	— 	69
Convertible debenture repurchases and
conversions 	— 	— 	(52) 	— 	— 	(52)
March 31, 2019 	257.4 	3 	9,482 	21,136 	(623) 	29,998
Net income 	— 	— 	— 	1,139 	— 	1,139
Other comprehensive income 	— 	— 	— 	— 	240 	240
Repurchase and retirement of common stock 	(1.7) 	— 	(70) 	(388) 	— 	(458)
Dividends and dividend equivalents 	— 	— 	— 	(208) 	— 	(208)
Issuance of common stock under employee stock
plans, net of related tax benefits 	0.2 	— 	91 	— 	— 	91
Convertible debenture repurchases and
conversions 	— 	— 	(9) 	— 	— 	(9)
June 30, 2019 	255.9 	$ 	3 	$ 	9,494 	$ 	21,679 	$ 	(383) 	$ 	30,793
See accompanying notes.
-7-

-- 10 of 72 --

Anthem, Inc.
Notes to Consolidated Financial Statements
(Unaudited)
June 30, 2020
(In Millions, Except Per Share Data or As Otherwise Stated Herein)
1. 	Organization
References to the terms “we,” “our,” “us” or “Anthem” used throughout these Notes to Consolidated Financial Statements refer to Anthem, Inc., an Indiana
corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of Columbia, unless the
context otherwise requires.
We are one of the largest health benefits companies in the United States in terms of medical membership, serving greater than 	42 	million 	medical members
through our affiliated health plans as of 	June 30, 2020. We offer a broad spectrum of network-based managed care plans to Large Group, Small Group, Individual,
Medicaid and Medicare markets. Our managed care plans include: Preferred Provider Organizations, or PPOs; Health Maintenance Organizations, or HMOs;
Point-of-Service plans; traditional indemnity plans and other hybrid plans, including Consumer-Driven Health Plans; and hospital only and limited benefit
products. In addition, we provide a broad array of managed care services to self-funded customers, including claims processing, stop loss insurance, actuarial
services, provider network access, medical cost management, disease management, wellness programs and other administrative services. We provide an array of
specialty and other insurance products and services such as pharmacy benefits management, or PBM, dental, vision, life and disability insurance benefits, radiology
benefit management and analytics-driven personal healthcare. We also provide services to the federal government in connection with our Federal Health Products
& Services business, which administers the Federal Employees Health Benefits, or FEHB, Program.
We are an independent licensee of the Blue Cross and Blue Shield Association, or BCBSA, an association of independent health benefit plans. 	We serve our
members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or BCBS, licensee for Colorado, Connecticut, Georgia, Indiana,
Kentucky, Maine, Missouri (excluding 	30 	counties in the Kansas City area), Nevada, New Hampshire, New York (in the New York City metropolitan area and
upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.) and Wisconsin. In a majority of these service areas, we do
business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross Blue Shield or Empire Blue Cross. We also conduct business through
arrangements with other BCBS licensees as well as other strategic partners. Through our subsidiaries, we also serve customers in numerous 	states across the
country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom Health, HealthLink, HealthSun, Optimum HealthCare, Simply
Healthcare, and/or Unicare. Also, in the second quarter of 2019, we began providing 	PBM services through our IngenioRx subsidiary. We are licensed to conduct
insurance operations in all 	50 	states and the District of Columbia through our subsidiaries.
2. 	Basis of Presentation and Significant Accounting Policies
Basis of Presentation: 	The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted
accounting principles, or GAAP, for interim financial reporting. Accordingly, they do not include all of the information and footnotes required by GAAP for
annual financial statements. We have omitted certain footnote disclosures that would substantially duplicate the disclosures in our 	2019 	Annual Report on Form
10-K, unless the information contained in those disclosures materially changed or is required by GAAP. Certain prior year amounts have been reclassified to
conform to the current year presentation. For additional information on prior year reclassifications, see Note 15, “Segment Information.” In the opinion of
management, all adjustments, including normal recurring adjustments, necessary for a fair statement of the consolidated financial statements as of and for the 	three
and six 	months ended 	June 30, 2020 	and 	2019 	have been recorded. The results of operations for the 	three and six 	months ended 	June 30, 2020 	are not necessarily
indicative of the results that may be expected for the full year ending 	December 31, 2020, or any other period. These unaudited consolidated financial statements
should be read in conjunction with our audited consolidated financial statements as of and for the year ended 	December 31, 2019 	included in our 	2019 	Annual
Report on Form 10-K.
Certain of our subsidiaries operate outside of the United States and have functional currencies other than the U.S. dollar, or USD. We translate the assets and
liabilities of those subsidiaries to USD using the exchange rate in effect at the end of the
-8-

-- 11 of 72 --

period. We translate the revenues and expenses of those subsidiaries to USD using the average exchange rates in effect during the period. The net effect of these
translation adjustments is included in “Foreign currency translation adjustments” in our consolidated statements of comprehensive income.
Cash and Cash Equivalents: 	We control a number of bank accounts that are used exclusively to hold customer funds for the administration of customer
benefits, and we have cash and cash equivalents on deposit to meet certain regulatory requirements. These amounts totaled 	$231 	and 	$215 	at 	June 30, 2020 	and
December 31, 2019, respectively, and are included in the cash and cash equivalents line on our consolidated balance sheets.
Investments: 	Prior to 2020, our fixed maturities were evaluated for other-than-temporary impairment where credit-related impairments were presented within
the other-than-temporary impairment losses recognized in our consolidated statements of income with an adjustment to the security’s amortized cost basis.
Effective January 1, 2020, if a fixed maturity security is in an unrealized loss position and we have the intent to sell the fixed maturity security, or it is more likely
than not that we will have to sell the fixed maturity security before recovery of its amortized cost basis, we write down the fixed maturity security’s cost basis to
fair value and record an impairment loss in our consolidated statements of income. For impaired fixed maturity securities that we do not intend to sell or if it is
more likely than not that we will not have to sell such securities, but we expect that we will not fully recover the amortized cost basis, we recognize the credit
component of the impairment as an allowance for credit loss in our consolidated balance sheets and record an impairment loss in our consolidated statements of
income. The non-credit component of the impairment is recognized in accumulated other comprehensive loss. Furthermore, unrealized losses entirely caused by
non-credit-related factors related to fixed maturity securities for which we expect to fully recover the amortized cost basis continue to be recognized in
accumulated other comprehensive loss.
The credit component of an impairment is determined primarily by comparing the net present value of projected future cash flows with the amortized cost
basis of the fixed maturity security. The net present value is calculated by discounting our best estimate of projected future cash flows at the effective interest rate
implicit in the fixed maturity security at the date of purchase. For mortgage-backed and asset-backed securities, cash flow estimates are based on assumptions
regarding the underlying collateral, including prepayment speeds, vintage, type of underlying asset, geographic concentrations, default rates, recoveries and
changes in value. For all other securities, cash flow estimates are driven by assumptions regarding probability of default, including changes in credit ratings and
estimates regarding timing and amount of recoveries associated with a default.
For asset-backed securities included in fixed maturity securities, we recognize income using an effective yield based on anticipated prepayments and the
estimated economic life of the securities. When estimates of prepayments change, the effective yield is recalculated to reflect actual payments to date and
anticipated future payments. The net investment in the securities is adjusted to the amount that would have existed had the new effective yield been applied since
the purchase date of the securities. Such adjustments are reported within net investment income.
In accordance with the Financial Accounting Standards Board, or FASB, guidance, the changes in fair value of our marketable equity securities are recognized
in our results of operations within net realized gains and losses on financial instruments.
We have corporate-owned life insurance policies on certain participants in our deferred compensation plans and other members of management. The cash
surrender value of the corporate-owned life insurance policies is reported under the caption “Other invested assets” in our consolidated balance sheets.
We use the equity method of accounting for investments in companies in which our ownership interest may enable us to influence the operating or financial
decisions of the investee company. Our proportionate share of equity in net income of these unconsolidated affiliates is reported within net investment income. The
equity method investments are reported under the caption “Other invested assets” in our consolidated balance sheets.
Investment income is recorded when earned. All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and
losses are determined on the basis of the cost or amortized cost of the specific securities sold.
-9-

-- 12 of 72 --

We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in
exchange for cash and securities collateral. Under FASB guidance related to accounting for transfers and servicing of financial assets and extinguishments of
liabilities, we recognize the collateral as an asset, which is reported under the caption “Other current assets” in our consolidated balance sheets, and we record a
corresponding liability for the obligation to return the collateral to the borrower, which is reported under the caption “Other current liabilities” in our consolidated
balance sheets. The securities on loan are reported in the applicable investment category on our consolidated balance sheets. Unrealized gains or losses on
securities lending collateral are included in accumulated other comprehensive loss as a separate component of shareholders’ equity. The market value of loaned
securities and that of the collateral pledged can fluctuate in non-synchronized fashions. To the extent the loaned securities’ value appreciates faster or depreciates
slower than the value of the collateral pledged, we are exposed to the risk of the shortfall. As a primary mitigating mechanism, the loaned securities and collateral
pledged are marked to market on a daily basis and the shortfall, if any, is collected accordingly. Secondarily, the collateral level is set at 	102% 	of the value of the
loaned securities, which provides a cushion before any shortfall arises. The investment of the cash collateral is subject to market risk, which is managed by limiting
the investments to higher quality and shorter duration instruments.
Receivables: 	Premium receivables include the uncollected amounts from insured groups, individuals and government programs. Premium receivables are
reported net of an allowance for doubtful accounts of 	$259 	and 	$237 	at June 30, 2020 and December 31, 2019, respectively. Self-funded receivables include
administrative fees, claims and other amounts due from self-funded customers.
Self-funded receivables are reported net of an allowance for doubtful accounts of 	$52 	and 	$46 	at June 30, 2020 and December 31, 2019, respectively. The
allowance for doubtful accounts is based on historical collection trends, future forecasts and our judgment regarding the ability to collect specific accounts.
Other receivables include pharmacy rebates, provider advances, claims recoveries, reinsurance receivables, proceeds due from brokers on investment trades,
other government receivables and other miscellaneous amounts due to us. These receivables are reported net of an allowance for doubtful accounts of 	$321 	and
$242 	at June 30, 2020 and December 31, 2019, respectively, which is based on historical collection trends, future forecasts and our judgment regarding the ability
to collect specific accounts.
Revenue Recognition: 	For our non-fully-insured contracts, we had no material contract assets, contract liabilities or deferred contract costs recorded on our
consolidated balance sheet at 	June 30, 2020. For the 	three and six 	months ended 	June 30, 2020, revenue recognized from performance obligations related to prior
periods, such as due to changes in transaction price, was not material. For contracts that have an original expected duration of greater than one year, revenue
expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration related to
undelivered performance obligations is not material.
Recently Adopted Accounting Guidance: 	In November 2019, the FASB issued Accounting Standards Update No. 2019-11, 	Codification Improvements to
Topic 326, Financial Instruments - Credit Losses. In May 2019, the FASB issued Accounting Standards Update No. 2019-05, 	Financial Instruments - Credit
Losses (Topic 326): Targeted Transition Relief. In April 2019, the FASB issued Accounting Standards Update No. 2019-04, 	Codification Improvements to Topic
326, Financial Instruments - Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments. In November 2018, the FASB issued
Accounting Standards Update No. 2018-19, 	Codification Improvements to Topic 326, Financial Instruments - Credit Losses. These updates provide an option to
irrevocably elect to measure certain individual financial assets at fair value instead of amortized cost and provide additional clarification and implementation
guidance on certain aspects of the previously issued Accounting Standards Update No. 2016-13, 	Financial Instruments - Credit Losses (Topic 326): Measurement
of Credit Losses on Financial Instruments, 	or ASU 2016-13, and have the same effective date and transition requirements as ASU 2016-13. ASU 2016-13
introduces a current expected credit loss model for measuring expected credit losses for certain types of financial instruments held at the reporting date based on
historical experience, current conditions and reasonable supportable forecasts. ASU 2016-13 replaces the current incurred loss model for measuring expected credit
losses, requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the
amortized cost of the securities and provides for additional disclosure requirements. ASU 2016-13 requires a cumulative-effect adjustment to the opening balance
of retained earnings on the statement of financial position at the date of adoption and a prospective transition approach for debt securities for which an other-than-
temporary impairment had been recognized before the adoption date. The effect of a prospective transition approach is to maintain the
-10-

-- 13 of 72 --

same amortized cost basis before and after the date of adoption. We adopted ASU 2016-13 on January 1, 2020, and recognized a cumulative-effect adjustment of
$35 	to our opening retained earnings for credit related allowances on receivables. The adoption did not have an impact on our consolidated statements of income or
cash flows.
In August 2018, the FASB issued Accounting Standards Update No. 2018-15, 	Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40):
Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract, or ASU 2018-15. The amendments in
ASU 2018-15 require implementation costs incurred by customers in cloud computing arrangements to be deferred and recognized over the term of the
arrangement, if those costs would be capitalized by the customer in a software licensing arrangement under the internal-use software guidance. The amendments
also require an entity to disclose the nature of its hosting arrangements and adhere to certain presentation requirements in its balance sheet, income statement and
statement of cash flows. We adopted ASU 2018-15 on January 1, 2020 using a prospective approach for all implementation costs incurred after the date of
adoption, and the adoption did not have an impact on our consolidated financial position, results of operations or cash flows.
In August 2018, the FASB issued Accounting Standards Update No. 2018-13, 	Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the
Disclosure Requirements for Fair Value Measurement, 	or ASU 2018-13. The amendments in ASU 2018-13 eliminate, add, and modify certain disclosure
requirements for fair value measurements. The amendments are effective for interim and annual periods beginning after December 15, 2019, with early adoption
permitted for either the entirety of ASU 2018-13 or only the provisions that eliminate or modify disclosure requirements. We early adopted the provisions that
eliminate and modify disclosure requirements, on a retrospective basis, effective in our 2018 Annual Report on Form 10-K. We adopted the new disclosure
requirements on January 1, 2020, on a prospective basis.
In January 2017, the FASB issued Accounting Standards Update No. 2017-04, 	Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for
Goodwill Impairment, or ASU 2017-04. This update removes Step 2 of the goodwill impairment test under current guidance, which required a hypothetical
purchase price allocation. The new guidance requires an impairment charge to be recognized for the amount by which the carrying amount exceeds the reporting
unit’s fair value. We adopted ASU 2017-04 on January 1, 2020, and the adoption did not have an impact on our consolidated financial position, results of
operations or cash flows.
Recent Accounting Guidance Not Yet Adopted: 	In March 2020, the FASB issued Accounting Standards Update No. 2020-04, 	Reference Rate Reform (Topic
848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting, or ASU 2020-04. ASU 2020-04 provides optional expedients and exceptions for
applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference the London Interbank Offered Rate, or
LIBOR, or another reference rate expected to be discontinued because of the reference rate reform. The provisions must be applied at a Topic, Subtopic, or
Industry Subtopic level for all transactions other than derivatives, which may be applied at a hedging relationship level. The provisions within ASU 2020-04 are
available until December 31, 2022, when the reference rate replacement activity is expected to have been completed. We are currently evaluating the provisions
within ASU 2020-04.
In December 2019, the FASB issued Accounting Standards Update No. 2019-12, 	Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, 	or
ASU 2019-12. The amendments in ASU 2019-12 remove certain exceptions to the general principles in Accounting Standards Codification Topic 740. The
amendments also clarify and amend existing guidance to improve consistent application. The amendments are effective for our annual reporting periods beginning
after December 15, 2020, with early adoption permitted. The transition method (retrospective, modified retrospective, or prospective basis) related to the
amendments depends on the applicable guidance, and all amendments for which there is no transition guidance specified are to be applied on a prospective basis.
We are currently evaluating the effects the adoption of ASU 2019-12 will have on our consolidated financial statements.
In August 2018, the FASB issued Accounting Standards Update No. 2018-14, 	Compensation—Retirement Benefits - Defined Benefit Plans—General
(Subtopic 715-20): Disclosure Framework—Changes to the Disclosure Requirements for Defined Benefit Plans, or ASU 2018-14. The amendments in ASU 2018-
14 eliminate, add, and modify certain disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans. The amendments
are effective for our annual reporting periods beginning after December 15, 2020, with early adoption permitted. The guidance is to be applied on a retrospective
basis to all periods presented. We are currently evaluating the effects the adoption of ASU 2018-14 will have on our disclosures.
-11-

-- 14 of 72 --

In August 2018, the FASB issued Accounting Standards Update No. 2018-12, 	Financial Services—Insurance (Topic 944): Targeted Improvements to the
Accounting for Long-Duration Contracts, 	or ASU 2018-12. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the
existing recognition, measurement, presentation and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require
insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The
amendments also simplify the amortization of deferred contract acquisition costs and add new disclosure requirements about the assumptions insurers use to
measure their liabilities and how they may affect future cash flows. The amendments in ASU 2018-12 will be effective for our interim and annual reporting periods
beginning after December 15, 2021. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred
acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments
retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk
benefits are to be applied retrospectively. We are currently evaluating the effects the adoption of ASU 2018-12 will have on our consolidated financial position,
results of operations, cash flows, and related disclosures.
There were no other new accounting pronouncements that were issued or became effective since the issuance of our 	2019 	Annual Report on Form 10-K that
had, or are expected to have, a material impact on our consolidated financial position, results of operations or cash flows.
3. 	Business Acquisition
Beacon Health Options, Inc.
On February 28, 2020, we completed our acquisition of Beacon Health Options, Inc., or Beacon, the largest independently held behavioral health organization
in the country. At the time of acquisition, Beacon served more than thirty-four million individuals across all fifty states. This acquisition aligns with our strategy to
diversify into health services and deliver both integrated solutions and care delivery models that personalize care for people with complex and chronic conditions.
In accordance with FASB accounting guidance for business combinations, the consideration transferred was allocated to the preliminary fair value of Beacon’s
assets acquired and liabilities assumed, including identifiable intangible assets. The excess of the consideration transferred over the preliminary fair value of net
assets acquired resulted in preliminary goodwill of $1,070 	at June 30, 2020, all of which was allocated to our Other segment. Preliminary goodwill recognized
from the acquisition of Beacon primarily relates to the future economic benefits arising from the assets acquired and is consistent with our stated intentions and
strategy. As of June 30, 2020, the initial accounting for the acquisition has not been finalized. Any additional payments or receipts of cash resulting from
contractual purchase price adjustments or any subsequent adjustments made to the assets acquired or liabilities assumed during the measurement period will
continue to be recorded as an adjustment to goodwill.
The preliminary fair value of the net assets acquired from Beacon includes 	$752 	of other intangible assets at June 30, 2020, which primarily consist of finite-
lived customer relationships with amortization periods ranging from 	9 	to 	21 	years. The results of operations of Beacon are included in our consolidated financial
statements within our Other segment for the period following February 28, 2020. The pro forma effects of this acquisition for prior periods were not material to our
consolidated results of operations.
4. 	Investments
Fixed Maturity Securities
We evaluate our available-for-sale fixed maturity securities for declines based on qualitative and quantitative factors. The effects of the COVID-19 global
health pandemic, or COVID-19, and other market related changes have impacted our fixed maturity securities. We have established an allowance for credit loss
and recorded credit loss expense as a reflection of our expected impairment losses. We continue to review our investment portfolios under our impairment review
policy. Given the inherent uncertainty of changes in market conditions and the significant judgments involved, there is a continuing risk that declines in fair value
may occur and additional material impairment losses on investments may be recorded in future periods.
-12-

-- 15 of 72 --

Our fixed maturity securities were in a net unrealized gain position of 	$713 	and 	$673 	at June 30, 2020 and December 31, 2019, respectively.
A summary of current and long-term fixed maturity securities, available-for-sale, at 	June 30, 2020 	and 	December 31, 2019 	is as follows:
Cost or
Amortized
Cost
Non-Credit
Component of
Impairment
Recognized in
Accumulated
Other
Comprehensive
Loss
Gross
Unrealized
Gains
Gross Unrealized Losses
Allowance For
Credit Losses
Estimated
Fair Value
Less than
12 Months
12 Months
or Greater
June 30, 2020
Fixed maturity securities:
United States Government securities 	$ 	1,250 	$ 	17 	$ 	(1) 	$ 	— 	$ 	— 	$ 	1,266 	$ 	—
Government sponsored securities 	96 	7 	(1) 	— 	— 	102 	—
Foreign government securities 	288 	7 	(15) 	— 	(1) 	279 	—
States, municipalities and political
subdivisions 	4,840 	315 	(5) 	— 	— 	5,150 	—
Corporate securities 	9,855 	469 	(125) 	(28) 	(23) 	10,148 	(32)
Residential mortgage-backed
securities 	3,696 	137 	(26) 	(11) 	— 	3,796 	—
Commercial mortgage-backed
securities 	80 	2 	(2) 	(4) 	— 	76 	—
Other securities 	1,744 	20 	(34) 	(9) 	— 	1,721 	—
Total fixed maturity securities 	$ 	21,849 	$ 	974 	$ 	(209) 	$ 	(52) 	$ 	(24) 	$ 	22,538 	$ 	(32)
December 31, 2019
Fixed maturity securities:
United States Government securities 	$ 	524 	$ 	4 	$ 	(3) 	$ 	— 	$ 	— 	$ 	525 	$ 	—
Government sponsored securities 	136 	5 	— 	— 	— 	141 	—
States, municipalities and political
subdivisions 	4,592 	262 	(3) 	— 	— 	4,851 	—
Corporate securities 	8,870 	339 	(9) 	(15) 	— 	9,185 	(3)
Residential mortgage-backed
securities 	3,654 	87 	(6) 	(3) 	— 	3,732 	—
Commercial mortgage-backed
securities 	84 	2 	— 	— 	— 	86 	—
Other securities 	1,648 	21 	(3) 	(5) 	— 	1,661 	—
Total fixed maturity securities 	$ 	19,508 	$ 	720 	$ 	(24) 	$ 	(23) 	$ 	— 	$ 	20,181 	$ 	(3)
-13-

-- 16 of 72 --

For fixed maturity securities in an unrealized loss position at 	June 30, 2020 	and 	December 31, 2019, the following table summarizes the aggregate fair values
and gross unrealized losses by length of time those securities have continuously been in an unrealized loss position:
Less than 12 Months 	12 Months or Greater
(Securities are whole amounts)
Number of
Securities
Estimated
Fair Value
Gross
Unrealized
Loss
Number of
Securities
Estimated
Fair Value
Gross
Unrealized
Loss
June 30, 2020
Fixed maturity securities:
United States Government securities 	5 	$ 	832 	$ 	(1) 	— 	$ 	— 	$ 	—
Government sponsored securities 	1 	1 	(1) 	1 	— 	—
Foreign government securities 	219 	161 	(15) 	— 	— 	—
States, municipalities and political subdivisions 	111 	221 	(5) 	3 	5 	—
Corporate securities 	1,813 	2,297 	(125) 	185 	211 	(28)
Residential mortgage-backed securities 	375 	654 	(26) 	78 	117 	(11)
Commercial mortgage-backed securities 	7 	17 	(2) 	3 	3 	(4)
Other securities 	381 	924 	(34) 	65 	161 	(9)
Total fixed maturity securities 	2,912 	$ 	5,107 	$ 	(209) 	335 	$ 	497 	$ 	(52)
December 31, 2019
Fixed maturity securities:
United States Government securities 	27 	$ 	250 	$ 	(3) 	2 	$ 	1 	$ 	—
Government sponsored securities 	14 	12 	— 	3 	1 	—
States, municipalities and political subdivisions 	114 	306 	(3) 	14 	11 	—
Corporate securities 	386 	558 	(9) 	224 	286 	(15)
Residential mortgage-backed securities 	321 	635 	(6) 	189 	237 	(3)
Commercial mortgage-backed securities 	1 	3 	— 	4 	8 	—
Other securities 	166 	415 	(3) 	113 	358 	(5)
Total fixed maturity securities 	1,029 	$ 	2,179 	$ 	(24) 	549 	$ 	902 	$ 	(23)
Below are discussions by security type for unrealized losses and credit losses as of June 30, 2020:
Foreign government securities: 	An allowance for credit loss was established on foreign government security holdings of Republic of Ecuador. Notification of the
request for delayed interest payments, a rating downgrade and significant decline in fair value were factors indicating a credit loss. No other foreign government
securities had material unrealized losses or qualitative factors to indicate a credit loss. We do not intend to sell these investments and it is likely we will not be
required to sell these investments prior to maturity or recovery of amortized cost.
Corporate securities: 	An allowance for credit losses on certain retail, travel and entertainment as well as energy sector fixed maturity corporate securities has been
determined based on qualitative and quantitative factors including credit rating, decline in fair value and industry condition along with other available market data.
With multiple risk factors present, these securities were reviewed for expected future cash flow to determine the portion of unrealized losses that were credit
related and to record an allowance for credit losses. Unrealized losses on our other corporate securities were largely due to market conditions relating to the
COVID-19 pandemic; however, qualitative factors did not indicate a credit loss as of June 30, 2020. We do not intend to sell these investments and it is likely we
will not have to sell these investments prior to maturity or recovery of amortized cost.
-14-

-- 17 of 72 --

As for the remaining securities shown in the table above, unrealized losses on these securities have not been recognized into income because we do not intend
to sell these investments and it is likely that we will not be required to sell these investments prior to their anticipated recovery. The decline in fair value is largely
due to changes in interest rates and other market conditions. We have evaluated these securities for any change in credit rating and have determined that no
allowance is necessary. The fair value is expected to recover as the securities approach maturity.
The table below presents a roll-forward by major security type of the allowance for credit losses on fixed maturity securities available-for-sale held at period
end for the 	three months ended June 30, 2020:
Three Months Ended June 30
Corporate
Securities
Foreign
Government
Securities 	Total
Allowance for credit losses:
Beginning balance 	$ 	51 	$ 	— 	$ 	51
Additions for securities for which no previous expected credit losses were recognized 	9 	1 	10
Securities sold during the period 	(8) 	— 	(8)
Increases (decreases) to the allowance for credit losses on securities 	(29) 	— 	(29)
Total allowance for credit losses 	$ 	23 	$ 	1 	$ 	24
The table below presents a roll-forward by major security type of the allowance for credit losses on fixed maturity securities available-for-sale held at period
end for the 	six months ended June 30, 2020:
Six Months Ended June 30
Corporate
Securities
Foreign
Government
Securities 	Total
Allowance for credit losses:
Beginning balance 	$ 	— 	$ 	— 	$ 	—
Additions for securities for which no previous expected credit losses were recognized 	60 	1 	61
Securities sold during the period 	(8) 	— 	(8)
Increases (decreases) to the allowance for credit losses on securities 	(29) 	— 	(29)
Total allowance for credit losses 	$ 	23 	$ 	1 	$ 	24
The amortized cost and fair value of fixed maturity securities at 	June 30, 2020, by contractual maturity, are shown below. Expected maturities may differ from
contractual maturities because the issuers of the securities may have the right to prepay obligations.
Amortized
Cost
Estimated
Fair Value
Due in one year or less 	$ 	1,481 	$ 	1,484
Due after one year through five years 	5,736 	5,876
Due after five years through ten years 	6,121 	6,340
Due after ten years 	4,735 	4,966
Mortgage-backed securities 	3,776 	3,872
Total fixed maturity securities 	$ 	21,849 	$ 	22,538
-15-

-- 18 of 72 --

Proceeds from sales, maturities, calls or redemptions of fixed maturity securities and the related gross realized gains and gross realized losses for the 	three and
six 	months ended 	June 30, 2020 	and 	2019 	are as follows:
Three Months Ended
June 30
Six Months Ended
June 30
2020 	2019 	2020 	2019
Proceeds 	$ 	2,618 	$ 	1,986 	$ 	4,549 	$ 	3,454
Gross realized gains 	37 	22 	80 	40
Gross realized losses 	(50) 	(17) 	(70) 	(34)
In the ordinary course of business, we may sell securities at a loss for a number of reasons, including, but not limited to: (i) changes in the investment
environment; (ii) expectation that the fair value could deteriorate further; (iii) desire to reduce exposure to an issuer or an industry; (iv) changes in credit quality; or
(v) changes in expected cash flow.
All securities sold resulting in investment gains and losses are recorded on the trade date. Realized gains and losses are determined on the basis of the cost or
amortized cost of the specific securities sold.
Equity Securities
A summary of marketable equity securities at 	June 30, 2020 	and 	December 31, 2019 	is as follows:
June 30, 2020 	December 31, 2019
Equity securities:
Exchange traded funds 	$ 	3,224 	$ 	44
Fixed maturity mutual funds 	152 	643
Common equity securities 	32 	237
Private equity securities 	62 	85
Total 	$ 	3,470 	$ 	1,009
The gains and losses related to equity securities for the 	three and six 	months ended 	June 30, 2020 	and 2019 are as follows:
Three Months Ended June 30 	Six Months Ended June 30
2020 	2019 	2020 	2019
Net realized gains (losses) recognized on equity securities 	$ 	45 	$ 	13 	$ 	(5) 	$ 	92
Less: Net realized losses (gains) recognized on equity securities sold during the period 	13 	(29) 	(5) 	(50)
Unrealized gains (losses) recognized on equity securities still held at June 30 	$ 	58 	$ 	(16) 	$ 	(10) 	$ 	42
Other Invested Assets
Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, as well as the cash
surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled corporations are carried at
our share in the entities’ undistributed earnings, which approximates fair value. Financial information for certain of these investments are reported on a one or three
month lag due to the timing of when we receive financial information from the companies. Given the recent market volatility, there is a risk that the value of some
of these investments may decline in future periods.
Investment Income
At June 30, 2020 and December 31, 2019, accrued investment income totaled 	$182 	and 	$173, respectively. We recognize accrued investment income under
the caption “Other receivables” on our consolidated balance sheets.
-16-

-- 19 of 72 --

Securities Lending Programs
We participate in securities lending programs whereby marketable securities in our investment portfolio are transferred to independent brokers or dealers in
exchange for cash and securities collateral. The fair value of the collateral received at the time of the transactions amounted to 	$1,114 	and 	$351 	at 	June 30, 2020
and 	December 31, 2019, respectively. The value of the collateral represented 	102% 	and 	103% 	of the market value of the securities on loan at 	June 30, 2020 	and
December 31, 2019, respectively. We recognize the collateral as an asset under the caption “Other current assets” in our consolidated balance sheets, and we
recognize a corresponding liability for the obligation to return the collateral to the borrower under the caption “Other current liabilities.” The securities on loan are
reported in the applicable investment category on our consolidated balance sheets.
The remaining contractual maturity of our securities lending agreements at 	June 30, 2020 	is as follows:
Overnight and
Continuous
Securities lending collateral
Cash 	$ 	961
United States Government securities 	151
Other securities 	2
Total 	$ 	1,114
5. 	Derivative Financial Instruments
We primarily invest in the following types of derivative financial instruments: interest rate swaps, futures, forward contracts, put and call options, swaptions,
embedded derivatives and warrants. We also enter into master netting agreements, which reduce credit risk by permitting net settlement of transactions.
We have entered into various interest rate swap contracts to convert a portion of our interest rate exposure on our long-term debt from fixed rates to floating
rates. The floating rates payable on all of our fair value hedges are benchmarked to LIBOR. Any amounts recognized for changes in fair value of these derivatives
are included in the captions “Other current or noncurrent assets” or “Other current or noncurrent liabilities” in our consolidated balance sheet.
Prior to 2020, we entered into a series of forward starting pay fixed interest rate swaps with the objective of reducing the variability of cash flows in the
interest payments on anticipated future financings. The unrecognized loss for all expired and terminated cash flow hedges included in accumulated other
comprehensive loss, net of tax, was 	$256 	and $262 	at 	June 30, 2020 	and 	December 31, 2019, respectively.
For additional information relating to the fair value of our derivative assets and liabilities, see Note 6, “Fair Value,” of this Form 10-Q.
6. 	Fair Value
Assets and liabilities recorded at fair value in our consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used
to measure their fair value. Level inputs, as defined by FASB guidance for fair value measurements and disclosures, are as follows:
Level Input 	Input Definition
Level I 	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II 	Inputs other than quoted prices included in Level I that are observable for the asset or liability through corroboration with market data at the
measurement date.
Level III 	Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the
measurement date.
-17-

-- 20 of 72 --

The following methods, assumptions and inputs were used to determine the fair value of each class of the following assets and liabilities recorded at fair value
in our consolidated balance sheets:
Cash equivalents: 	Cash equivalents primarily consist of highly rated money market funds with maturities of three months or less and are purchased daily at
par value with specified yield rates. Due to the high ratings and short-term nature of the funds, we designate all cash equivalents as Level I.
Fixed maturity securities, available-for-sale: 	Fair values of available-for-sale fixed maturity securities are based on quoted market prices, where available.
These fair values are obtained primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value to
facilitate fair value measurements and disclosures. Level II securities primarily include corporate securities, securities from states, municipalities and political
subdivisions, mortgage-backed securities, United States Government securities, foreign government securities, and certain other asset-backed securities. For
securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs
that are currently observable in the markets for similar securities. We have controls in place to review the pricing services’ qualifications and procedures used to
determine fair values. In addition, we periodically review the pricing services’ pricing methodologies, data sources and pricing inputs to ensure the fair values
obtained are reasonable. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads,
default rates and prepayment speeds. We also have certain fixed maturity securities, primarily corporate debt securities, which are designated Level III securities.
For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected
cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.
Equity securities: 	Fair values of equity securities are generally designated as Level I and are based on quoted market prices. For certain equity securities,
quoted market prices for the identical security are not always available, and the fair value is estimated by reference to similar securities for which quoted prices are
available. These securities are designated Level II. We also have certain equity securities, including private equity securities, for which the fair value is estimated
based on each security’s current condition and future cash flow projections. Such securities are designated Level III. The fair values of these private equity
securities are generally based on either broker quotes or discounted cash flow projections using assumptions for inputs such as the weighted-average cost of capital,
long-term revenue growth rates and earnings before interest, taxes, depreciation and amortization, and/or revenue multiples that are not observable in the markets.
Securities lending collateral: 	Fair values of securities lending collateral are based on quoted market prices, where available. These fair values are obtained
primarily from third-party pricing services, which generally use Level I or Level II inputs for the determination of fair value, to facilitate fair value measurements
and disclosures.
Derivatives: 	Fair values are based on the quoted market prices by the financial institution that is the counterparty to the derivative transaction. We
independently verify prices provided by the counterparties using valuation models that incorporate observable market inputs for similar derivative transactions.
Derivatives are designated as Level II securities. Derivatives presented within the fair value hierarchy table below are presented on a gross basis and not on a
master netting basis by counterparty.
-18-

-- 21 of 72 --

A summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis at 	June 30, 2020 	and 	December 31, 2019 	is
as follows:
Level I 	Level II 	Level III 	Total
June 30, 2020
Assets:
Cash equivalents 	$ 	3,809 	$ 	— 	$ 	— 	$ 	3,809
Fixed maturity securities, available-for-sale:
United States Government securities 	— 	1,266 	— 	1,266
Government sponsored securities 	— 	102 	— 	102
Foreign government securities 	— 	279 	— 	279
States, municipalities and political subdivisions, tax-exempt 	— 	5,150 	— 	5,150
Corporate securities 	— 	9,834 	314 	10,148
Residential mortgage-backed securities 	— 	3,794 	2 	3,796
Commercial mortgage-backed securities 	— 	76 	— 	76
Other securities 	— 	1,716 	5 	1,721
Total fixed maturity securities, available-for-sale 	— 	22,217 	321 	22,538
Equity securities:
Exchange traded funds 	3,224 	— 	— 	3,224
Fixed maturity mutual funds 	— 	152 	— 	152
Common equity securities 	1 	31 	— 	32
Private equity securities 	— 	— 	62 	62
Total equity securities 	3,225 	183 	62 	3,470
Securities lending collateral 	— 	1,114 	— 	1,114
Derivatives 	— 	50 	— 	50
Total assets 	$ 	7,034 	$ 	23,564 	$ 	383 	$ 	30,981
Liabilities:
Derivatives 	$ 	— 	$ 	— 	$ 	— 	$ 	—
Total liabilities 	$ 	— 	$ 	— 	$ 	— 	$ 	—
December 31, 2019
Assets:
Cash equivalents 	$ 	2,015 	$ 	— 	$ 	— 	$ 	2,015
Fixed maturity securities, available-for-sale:
United States Government securities 	— 	525 	— 	525
Government sponsored securities 	— 	141 	— 	141
States, municipalities and political subdivisions, tax-exempt 	— 	4,851 	— 	4,851
Corporate securities 	— 	8,882 	303 	9,185
Residential mortgage-backed securities 	— 	3,730 	2 	3,732
Commercial mortgage-backed securities 	— 	86 	— 	86
Other securities 	— 	1,654 	7 	1,661
Total fixed maturity securities, available-for-sale 	— 	19,869 	312 	20,181
Equity securities:
Exchange traded funds 	44 	— 	— 	44
Fixed maturity mutual funds 	— 	643 	— 	643
Common equity securities 	206 	31 	— 	237
Private equity securities 	— 	— 	85 	85
Total equity securities 	250 	674 	85 	1,009
Securities lending collateral 	— 	353 	— 	353
Derivatives 	— 	23 	— 	23
Total assets 	$ 	2,265 	$ 	20,919 	$ 	397 	$ 	23,581
Liabilities:
Derivatives 	$ 	— 	$ 	(1) 	$ 	— 	$ 	(1)
Total liabilities 	$ 	— 	$ 	(1) 	$ 	— 	$ 	(1)

-- 22 of 72 --

-19-

-- 23 of 72 --

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the three months ended
June 30, 2020 and 2019 is as follows:
Corporate
Securities
Residential
Mortgage-
backed
Securities
Other
Securities
Equity
Securities 	Total
Three Months Ended June 30, 2020
Beginning balance at April 1, 2020 	$ 	316 	$ 	2 	$ 	5 	$ 	82 	$ 	405
Total gains (losses):
Recognized in net income 	1 	— 	— 	(10) 	(9)
Recognized in accumulated other comprehensive loss 	(7) 	— 	— 	— 	(7)
Purchases 	14 	— 	— 	3 	17
Sales 	(1) 	— 	— 	(13) 	(14)
Settlements 	(9) 	— 	— 	— 	(9)
Transfers into Level III 	— 	— 	— 	— 	—
Transfers out of Level III 	— 	— 	— 	— 	—
Ending balance at June 30, 2020 	$ 	314 	$ 	2 	$ 	5 	$ 	62 	$ 	383
Change in unrealized losses included in net income related to assets still held at June 30, 2020 	$ 	— 	$ 	— 	$ 	— 	$ 	(10) 	$ 	(10)
Three Months Ended June 30, 2019
Beginning balance at April 1, 2019 	$ 	297 	$ 	6 	$ 	14 	$ 	297 	$ 	614
Total (losses) gains:
Recognized in net income 	(3) 	— 	— 	2 	(1)
Recognized in accumulated other comprehensive loss 	— 	— 	— 	— 	—
Purchases 	30 	— 	— 	14 	44
Sales 	(1) 	— 	— 	(8) 	(9)
Settlements 	(19) 	(1) 	(1) 	— 	(21)
Transfers into Level III 	— 	— 	— 	— 	—
Transfers out of Level III 	(7) 	(2) 	(2) 	— 	(11)
Ending balance at June 30, 2019 	$ 	297 	$ 	3 	$ 	11 	$ 	305 	$ 	616
Change in unrealized gains included in net income related to assets still held at June 30, 2019 	$ 	— 	$ 	— 	$ 	— 	$ 	(2) 	$ 	(2)
-20-

-- 24 of 72 --

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level III inputs for the 	six months ended June
30, 2020 	and 	2019 	is as follows:
Corporate
Securities
Residential
Mortgage-
backed
Securities
Other
Securities
Equity
Securities 	Total
Six Months Ended June 30, 2020
Beginning balance at January 1, 2020 	$ 	303 	$ 	2 	$ 	7 	$ 	85 	$ 	397
Total losses:
Recognized in net income 	(1) 	— 	— 	(16) 	(17)
Recognized in accumulated other comprehensive loss 	(17) 	— 	— 	— 	(17)
Purchases 	39 	— 	— 	15 	54
Sales 	(4) 	— 	— 	(22) 	(26)
Settlements 	(19) 	— 	(2) 	— 	(21)
Transfers into Level III 	13 	— 	— 	— 	13
Transfers out of Level III 	— 	— 	— 	— 	—
Ending balance at June 30, 2020 	$ 	314 	$ 	2 	$ 	5 	$ 	62 	$ 	383
Change in unrealized losses included in net income related to assets still held at June 30, 2020 	$ 	— 	$ 	— 	$ 	— 	$ 	(17) 	$ 	(17)
Six Months Ended June 30, 2019
Beginning balance at January 1, 2019 	$ 	287 	$ 	6 	$ 	17 	$ 	313 	$ 	623
Total (losses) gains:
Recognized in net income 	(4) 	— 	— 	— 	(4)
Recognized in accumulated other comprehensive loss 	2 	— 	— 	— 	2
Purchases 	63 	— 	2 	21 	86
Sales 	(2) 	— 	— 	(29) 	(31)
Settlements 	(40) 	(1) 	(2) 	— 	(43)
Transfers into Level III 	— 	— 	3 	— 	3
Transfers out of Level III 	(9) 	(2) 	(9) 	— 	(20)
Ending balance at June 30, 2019 	$ 	297 	$ 	3 	$ 	11 	$ 	305 	$ 	616
Change in unrealized gains included in net income related to assets still held at June 30, 2019 	$ 	— 	$ 	— 	$ 	— 	$ 	— 	$ 	—
There were no individually material transfers into or out of Level III during the 	three and six 	months ended 	June 30, 2020 	or 	2019.
Certain assets and liabilities are measured at fair value on a nonrecurring basis; that is, the instruments are not measured at fair value on an ongoing basis but
are subject to fair value adjustments only in certain circumstances. As disclosed in Note 3, “Business Acquisitions,” we completed our acquisition of Beacon
on February 28, 2020. The preliminary values of net assets acquired in our acquisition of Beacon and resulting goodwill and other intangible assets were recorded
at fair value primarily using Level III inputs. The majority of Beacon’s assets acquired and liabilities assumed were recorded at their carrying values as of
the respective date of acquisition, as their carrying values approximated their fair values due to their short-term nature. The preliminary fair values of goodwill and
other intangible assets acquired in our acquisition of Beacon were internally estimated based on the income approach. The income approach estimates fair value
based on the present value of the cash flows that the assets could be expected to generate in the future. We developed internal estimates for the expected cash flows
and discount rate in the present value calculation. Other than the assets acquired and liabilities assumed in our acquisition of Beacon described above, there were
no material assets or liabilities measured at fair value on a nonrecurring basis during the 	three and six 	months ended 	June 30, 2020 	or 	2019.
-21-

-- 25 of 72 --

Our valuation policy is determined by members of our treasury and accounting departments. Whenever possible, our policy is to obtain quoted market prices
in active markets to estimate fair values for recognition and disclosure purposes. Where quoted market prices in active markets are not available, fair values are
estimated using discounted cash flow analyses, broker quotes, unobservable inputs or other valuation techniques. These techniques are significantly affected by our
assumptions, including discount rates and estimates of future cash flows. The use of assumptions for unobservable inputs for the determination of fair value
involves a level of judgment and uncertainty. Changes in assumptions that reasonably could have been different at the reporting date may result in a higher or
lower determination of fair value. Changes in fair value measurements, if significant, may affect performance of cash flows.
Potential taxes and other transaction costs are not considered in estimating fair values. Our valuation policy is generally to obtain quoted prices for each
security from third-party pricing services, which are derived through recently reported trades for identical or similar securities making adjustments through the
reporting date based upon available market observable information. As we are responsible for the determination of fair value, we perform analysis on the prices
received from the pricing services to determine whether the prices are reasonable estimates of fair value. This analysis is performed by our internal treasury
personnel who are familiar with our investment portfolios, the pricing services engaged and the valuation techniques and inputs used. Our analysis includes
procedures such as a review of month-to-month price fluctuations and price comparisons to secondary pricing services. There were no adjustments to quoted
market prices obtained from the pricing services during the 	three and six 	months ended 	June 30, 2020 	or 	2019.
In addition to the preceding disclosures on assets recorded at fair value in the consolidated balance sheets, FASB guidance also requires the disclosure of fair
values for certain other financial instruments for which it is practicable to estimate fair value, whether or not such values are recognized in our consolidated
balance sheets.
Non-financial instruments such as real estate, property and equipment, other current assets, deferred income taxes, intangible assets and certain financial
instruments, such as policy liabilities, are excluded from the fair value disclosures. Therefore, the fair value amounts cannot be aggregated to determine our
underlying economic value.
The carrying amounts for cash, accrued investment income, premium receivables, self-funded receivables, other receivables, income taxes receivable/payable,
unearned income, accounts payable and accrued expenses, security trades pending payable, securities lending payable and certain other current liabilities
approximate fair value because of the short term nature of these items. These assets and liabilities are not listed in the table below.
The following methods and assumptions were used to estimate the fair value of each class of financial instrument that is recorded at its carrying value in our
consolidated balance sheets:
Other invested assets: 	Other invested assets include primarily our investments in limited partnerships, joint ventures and other non-controlled corporations, as
well as the cash surrender value of corporate-owned life insurance policies. Investments in limited partnerships, joint ventures and other non-controlled
corporations are carried at our share in the entities’ undistributed earnings, which approximates fair value. The carrying value of corporate-owned life insurance
policies represents the cash surrender value as reported by the respective insurer, which approximates fair value.
Short-term borrowings: 	The fair value of our short-term borrowings is based on quoted market prices for the same or similar debt, or, if no quoted market
prices were available, on the current market interest rates estimated to be available to us for debt of similar terms and remaining maturities.
Long-term debt – commercial paper: 	The carrying amount for commercial paper approximates fair value, as the underlying instruments have variable interest
rates at market value.
Long-term debt – senior unsecured notes and surplus notes: 	The fair values of our notes are based on quoted market prices in active markets for the same or
similar debt, or, if no quoted market prices are available, on the current market observable rates estimated to be available to us for debt of similar terms and
remaining maturities.
Long-term debt – convertible debentures: 	The fair value of our convertible debentures is based on the quoted market price in the active private market in
which the convertible debentures trade.
-22-

-- 26 of 72 --

A summary of the estimated fair values by level of each class of financial instrument that is recorded at its carrying value on our consolidated balance sheets at
June 30, 2020 	and 	December 31, 2019 	is as follows:
Carrying
Value
Estimated Fair Value
Level I 	Level II 	Level III 	Total
June 30, 2020
Assets:
Other invested assets 	$ 	4,097 	$ 	— 	$ 	— 	$ 	4,097 	$ 	4,097
Liabilities:
Debt:
Notes 	21,358 	— 	24,273 	— 	24,273
Convertible debentures 	118 	— 	426 	— 	426
December 31, 2019
Assets:
Other invested assets 	$ 	4,258 	$ 	— 	$ 	— 	$ 	4,258 	$ 	4,258
Liabilities:
Debt:
Short-term borrowings 	700 	— 	700 	— 	700
Commercial paper 	400 	— 	400 	— 	400
Notes 	18,840 	— 	20,470 	— 	20,470
Convertible debentures 	145 	— 	904 	— 	904
7. 	Income Taxes
During the 	three months ended June 30, 2020 	and 	2019, we recognized income tax expense of 	$873 	and 	$314, respectively, which represent effective tax rates
of 	27.7% 	and 	21.6%, respectively. The 	increase 	in our effective tax rate was primarily due to the reinstatement of the non-tax deductible Health Insurance Provider
Fee, or HIP Fee, for 2020.
During the 	six months ended June 30, 2020 	and 	2019, we recognized income tax expense of 	$1,439 	and 	$708, respectively, which represent effective tax rates
of 	27.5% 	and 	20.8%, respectively. The 	increase 	in our effective income tax rate was primarily due to the reinstatement of the non-tax deductible HIP Fee for 2020.
Income taxes payable totaled 	$978 	at June 30, 2020. Income taxes receivable totaled 	$335 	at 	December 31, 2019. We recognize the income tax payable as a
liability under the caption “Other current liabilities” and the income tax receivable as an asset under the caption “Other current assets” in our consolidated balance
sheets.
-23-

-- 27 of 72 --

8. 	Retirement Benefits
The components of net periodic benefit credit included in our consolidated statements of income for the three months ended June 30, 2020 and 2019 are as
follows:
Pension Benefits 	Other Benefits
Three Months Ended
June 30
Three Months Ended
June 30
2020 	2019 	2020 	2019
Interest cost 	$ 	13 	$ 	16 	$ 	2 	$ 	4
Expected return on assets 	(29) 	(35) 	(6) 	(6)
Recognized actuarial loss 	6 	4 	— 	1
Settlement loss 	10 	2 	— 	—
Amortization of prior service credit 	— 	— 	(2) 	(3)
Net periodic benefit credit 	$ 	— 	$ 	(13) 	$ 	(6) 	$ 	(4)
The components of net periodic benefit credit included in our consolidated statements of income for the 	six months ended June 30, 2020 	and 	2019 	are as
follows:
Pension Benefits 	Other Benefits
Six Months Ended
June 30
Six Months Ended
June 30
2020 	2019 	2020 	2019
Interest cost 	$ 	25 	$ 	32 	$ 	5 	$ 	8
Expected return on assets 	(69) 	(69) 	(12) 	(11)
Recognized actuarial loss 	12 	8 	— 	1
Settlement loss 	15 	4 	— 	—
Amortization of prior service credit 	— 	— 	(4) 	(6)
Net periodic benefit credit 	$ 	(17) 	$ 	(25) 	$ 	(11) 	$ 	(8)
For the year ending 	December 31, 2020, no material contributions are expected to be necessary to meet the Employee Retirement Income Security Act of
1974, as amended, or ERISA, required funding levels; however, we may elect to make discretionary contributions up to the maximum amount deductible for
income tax purposes. Contributions of 	$3 	and 	$0 	were made to our retirement benefit plans during the 	six months ended June 30, 2020 	and 	2019.
-24-

-- 28 of 72 --

9. 	Medical Claims Payable
A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the 	six months
ended June 30, 2020 	is as follows:
Commercial
& Specialty
Business
Government
Business 	Other 	Total
Gross medical claims payable, beginning of period 	$ 	3,039 	$ 	5,608 	$ 	— 	$ 	8,647
Ceded medical claims payable, beginning of period 	(14) 	(19) 	— 	(33)
Net medical claims payable, beginning of period 	3,025 	5,589 	— 	8,614
Business combinations and purchase adjustments 	— 	141 	198 	339
Net incurred medical claims:
Current period 	11,318 	28,162 	498 	39,978
Prior periods redundancies 	(374) 	(326) 	— 	(700)
Total net incurred medical claims 	10,944 	27,836 	498 	39,278
Net payments attributable to:
Current period medical claims 	9,014 	22,115 	496 	31,625
Prior periods medical claims 	2,218 	4,823 	— 	7,041
Total net payments 	11,232 	26,938 	496 	38,666
Net medical claims payable, end of period 	2,737 	6,628 	200 	9,565
Ceded medical claims payable, end of period 	62 	28 	— 	90
Gross medical claims payable, end of period 	$ 	2,799 	$ 	6,656 	$ 	200 	$ 	9,655
Activity in the Other segment resulted from our acquisition of Beacon.
At 	June 30, 2020, the total of net incurred but not reported liabilities plus expected development on reported claims for the Commercial & Specialty Business
was 	$74, 	$358 	and 	$2,305 	for the claim years 2018 and prior, 2019 and 2020, respectively.
At 	June 30, 2020, the total of net incurred but not reported liabilities plus expected development on reported claims for the Government Business was 	$80,
$360 	and 	$6,188 	for the claim years 2018 and prior, 2019 and 2020, respectively.
At 	June 30, 2020, the total of net incurred but not reported liabilities plus expected development on reported claims for Other was 	$0, 	$0 	and 	$200 	for the
claim years 2018 and prior, 2019 and 2020, respectively.
-25-

-- 29 of 72 --

A reconciliation of the beginning and ending balances for medical claims payable, by segment (see Note 15, “Segment Information”), for the 	six months
ended June 30, 2019 	is as follows:
Commercial
& Specialty
Business
Government
Business 	Other 	Total
Gross medical claims payable, beginning of period 	$ 	2,586 	$ 	4,680 	$ 	— 	$ 	7,266
Ceded medical claims payable, beginning of period 	(10) 	(24) 	— 	(34)
Net medical claims payable, beginning of period 	2,576 	4,656 	— 	7,232
Net incurred medical claims:
Current period 	12,460 	25,777 	— 	38,237
Prior periods redundancies 	(182) 	(232) 	— 	(414)
Total net incurred medical claims 	12,278 	25,545 	— 	37,823
Net payments attributable to:
Current period medical claims 	9,928 	20,439 	— 	30,367
Prior periods medical claims 	2,081 	4,101 	— 	6,182
Total net payments 	12,009 	24,540 	— 	36,549
Net medical claims payable, end of period 	2,845 	5,661 	— 	8,506
Ceded medical claims payable, end of period 	14 	29 	— 	43
Gross medical claims payable, end of period 	$ 	2,859 	$ 	5,690 	$ 	— 	$ 	8,549
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 	2020 	are as follows:
Three Months Ended Six Months Ended
June 30, 2020	March 31, 2020 	June 30, 2020
Net incurred medical claims:
Commercial & Specialty Business 	$ 	5,797 	$ 	5,147 	$ 	10,944
Government Business 	14,603 	13,233 	27,836
Other 	130 	368 	498
Total net incurred medical claims 	20,530 	18,748 	39,278
Quality improvement and other claims expense 	959 	799 	1,758
Benefit expense 	$ 	21,489 	$ 	19,547 	$ 	41,036
The reconciliation of net incurred medical claims to benefit expense included in our consolidated statements of income for periods in 	2019 	are as follows:
Three Months Ended Six Months Ended
June 30, 2019	March 31, 2019 	June 30, 2019
Net incurred medical claims:
Commercial & Specialty Business 	$ 	5,856 	$ 	6,422 	$ 	12,278
Government Business 	12,483 	13,062 	25,545
Total net incurred medical claims 	18,339 	19,484 	37,823
Quality improvement and other claims expense 	943 	884 	1,827
Benefit expense 	$ 	19,282 	$ 	20,368 	$ 	39,650
-26-

-- 30 of 72 --

The reconciliation of the medical claims payable reflected in the tables above to the consolidated ending balance for medical claims payable included in the
consolidated balance sheet, as of 	June 30, 2020, is as follows:
Commercial
& Specialty
Business
Government
Business 	Other 	Total
Net medical claims payable, end of period 	$ 	2,737 	$ 	6,628 	$ 	200 	$ 	9,565
Ceded medical claims payable, end of period 	62 	28 	— 	90
Insurance lines other than short duration 	— 	223 	— 	223
Gross medical claims payable, end of period 	$ 	2,799 	$ 	6,879 	$ 	200 	$ 	9,878
10. 	Debt
We generally issue senior unsecured notes for long-term borrowing purposes. At 	June 30, 2020 	and 	December 31, 2019, we had 	$21,333 	and 	$18,815,
respectively, outstanding under these notes.
We have an unsecured surplus note with an outstanding principal balance of 	$25 	at both 	June 30, 2020 	and 	December 31, 2019.
On May 5, 2020, we issued 	$400 	aggregate principal amount of additional senior notes pursuant to a reopening of our existing 	2.375% 	Notes due 2025, or the
2025 Notes, 	$1,100 	aggregate principal amount of 	2.250% 	Notes due 2030, or the 2030 Notes, and 	$1,000 	aggregate principal amount of 	3.125% 	Notes due 2050,
or the 2050 Notes, under our shelf registration statement. The 2025 Notes constitute an additional issuance of our 	2.375% 	notes due 2025, of which 	$850 	aggregate
principal amount was issued on September 9, 2019. 	Interest on the 2025 Notes is deemed to have accrued from January 15, 2020 and is payable semi-annually in
arrears on January 15 and July 15 of each year, commencing July 15, 2020. Interest on the 2030 and 2050 Notes is payable semi-annually in arrears on May 15 and
November 15 of each year, commencing November 15, 2020. We intend to use net proceeds for working capital and general corporate purposes, including, but not
limited to, repayment of short-term and long-term debt, repurchase of our common stock pursuant to our share repurchase program and to fund acquisitions.
We have a senior revolving credit facility, or the 5-Year Facility, with a group of lenders for general corporate purposes. The 5-Year Facility provides credit
up to 	$2,500 	and matures in June 2024. We also have a 364-day senior revolving credit facility, or 364-Day Facility, with a group of lenders for general corporate
purposes, which provides for credit in the amount of 	$1,000. In May 2020, we amended and extended the 364-Day Facility, which now matures in June 2021. 	Our
ability to borrow under these credit facilities is subject to compliance with certain covenants, including covenants requiring us to maintain a defined debt-to-capital
ratio of not more than 60%, subject to increase in certain circumstances set forth in the applicable credit agreement. 	As of June 30, 2020, our debt-to-capital ratio,
as defined and calculated under the credit facilities, was 38.4%. We do not believe the restrictions contained in any of our credit facility covenants materially affect
our financial or operating flexibility. 	As of June 30, 2020, we were in compliance with all of the debt covenants under these credit facilities. 	There were no
amounts outstanding under the 364-Day Facility at any time during the 	six months ended 	June 30, 2020 	or the year ended 	December 31, 2019. At June 30, 2020
and December 31, 2019, there were no amounts outstanding under our 5-Year Facility.
Through certain subsidiaries, we have entered into multiple 364-day lines of credit, or the Subsidiary Credit Facilities, with separate lenders for general
corporate purposes. The Subsidiary Credit Facilities provide combined credit of up to 	$400. At 	June 30, 2020 	and 	December 31, 2019, 	$0 	and 	$50, respectively,
were outstanding under our Subsidiary Credit Facilities.
We have an authorized commercial paper program of up to 	$3,500, the proceeds of which may be used for general corporate purposes. At 	June 30, 2020 	and
December 31, 2019, we had 	$0 	and 	$400, respectively, outstanding under this program.
We have outstanding senior unsecured convertible debentures due 2042, or the Debentures, which are governed by an indenture between us and The Bank of
New York Mellon Trust Company, N.A., as trustee, or the indenture. We have accounted for the Debentures in accordance with the FASB cash conversion
guidance for debt with conversion and other options. As a result, the value of the embedded conversion option (net of deferred taxes and equity issuance costs) has
been
-27-

-- 31 of 72 --

bifurcated from its debt host and recorded as a component of additional paid-in capital in our consolidated balance sheets. During the 	three and six months ended
June 30, 2020, 	$27 	and 	$40, respectively, of aggregate principal amount of the Debentures were surrendered for conversion by certain holders in accordance with
the terms and provisions of the indenture. We elected to settle the excess of the principal amount of the conversions with cash for total payments during the 	three
and six months ended 	June 30, 2020 	of 	$103 	and 	$155, respectively. We recognized a loss on the extinguishment of debt related to the Debentures of 	$3 	and 	$4,
respectively, for the 	three and six months ended 	June 30, 2020, based on the fair values of the debt on the conversion settlement dates.
The following table summarizes at 	June 30, 2020 	the related balances, conversion rate and conversion price of the Debentures:
Outstanding principal amount 	$ 	175
Unamortized debt discount 	$ 	55
Net debt carrying amount 	$ 	118
Equity component carrying amount 	$ 	63
Conversion rate (shares of common stock per $1,000 of principal amount) 	14.0171
Effective conversion price (per $1,000 of principal amount) 	$ 	71.3414
We are a member, through certain subsidiaries, of the Federal Home Loan Bank of Indianapolis, the Federal Home Loan Bank of Cincinnati and the Federal
Home Loan Bank of Atlanta, or collectively, the FHLBs. As a member, we have the ability to obtain short-term cash advances, subject to certain minimum
collateral requirements. We had 	$0 	and 	$650 	in outstanding short-term borrowings from the FHLBs at 	June 30, 2020 	and 	December 31, 2019, respectively, with a
fixed interest rate of 	1.664% 	for the December 31, 2019 borrowing.
All debt is a direct obligation of Anthem, Inc., except for the surplus note, the FHLB borrowings, and the Subsidiary Credit Facilities.
11. 	Commitments and Contingencies
Litigation and Regulatory Proceedings
In the ordinary course of business, we are defendants in, or parties to, a number of pending or threatened legal actions or proceedings. To the extent a plaintiff
or plaintiffs in the following cases have specified in their complaint or in other court filings the amount of damages being sought, we have noted those alleged
damages in the descriptions below. With respect to the cases described below, we contest liability and/or the amount of damages in each matter and believe we
have meritorious defenses.
Where available information indicates that it is probable that a loss has been incurred as of the date of the consolidated financial statements and we can
reasonably estimate the amount of that loss, we accrue the estimated loss by a charge to income. In many proceedings, however, it is difficult to determine whether
any loss is probable or reasonably possible. In addition, even where loss is possible or an exposure to loss exists in excess of the liability already accrued with
respect to a previously identified loss contingency, it is not always possible to reasonably estimate the amount of the possible loss or range of loss.
With respect to many of the proceedings to which we are a party, we cannot provide an estimate of the possible losses, or the range of possible losses in excess
of the amount, if any, accrued, for various reasons, including but not limited to some or all of the following: (i) there are novel or unsettled legal issues presented,
(ii) the proceedings are in early stages, (iii) there is uncertainty as to the likelihood of a class being certified or decertified or the ultimate size and scope of the
class, (iv) there is uncertainty as to the outcome of pending appeals or motions, (v) there are significant factual issues to be resolved, and/or (vi) in many cases, the
plaintiffs have not specified damages in their complaint or in court filings. For those legal proceedings where a loss is probable, or reasonably possible, and for
which it is possible to reasonably estimate the amount of the possible loss or range of losses, we currently believe that the range of possible losses, in excess of
established reserves is, in the aggregate, from 	$0 	to approximately 	$800 	at 	June 30, 2020. This estimated aggregate range
-28-

-- 32 of 72 --

of reasonably possible losses is based upon currently available information taking into account our best estimate of such losses for which such an estimate can be
made.
Blue Cross Blue Shield Antitrust Litigation
We are a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees, or Blue plans, across
the country. The cases were consolidated into a single, multi-district proceeding captioned 	In re Blue Cross Blue Shield Antitrust Litigation 	that is pending in the
United States District Court for the Northern District of Alabama, or the Court. Generally, the suits allege that the BCBSA and the Blue plans have conspired to
horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on
acquisitions, rules governing the BlueCard and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act, or Sherman Act,
and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers, and the actions filed in
twenty-eight states have been consolidated into the multi-district proceeding.
In response to cross motions for partial summary judgment by plaintiffs and defendants, the Court issued an order in April 2018 determining that the
defendants’ aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard program
and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. The Court also found that there remain genuine
issues of material fact as to whether defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks. No dates have
been set for either the final pretrial conferences or trials in these actions. In April 2019, plaintiffs filed their motions for class certification in conjunction with their
supporting expert reports, and the defendants filed their motions to exclude plaintiffs’ experts, as well as their opposition to plaintiffs’ motions for class
certification, in July 2019. The case has been stayed by the Court until further notice.
We intend to vigorously defend these suits; however, their ultimate outcome cannot be presently determined.
Blue Cross of California Taxation Litigation
In July 2013, our California affiliate Blue Cross of California (doing business as Anthem Blue Cross), or BCC, was named as a defendant in a California
taxpayer action filed in Los Angeles County Superior Court, or the Superior Court, captioned 	Michael D. Myers v. State Board of Equalization, et al. 	This action
was brought under a California statute that permits an individual taxpayer to sue a governmental agency when the taxpayer believes the agency has failed to
enforce governing law. Plaintiff contends that BCC, a licensed Health Care Service Plan, or HCSP, is an “insurer” for purposes of taxation despite acknowledging
it is not an “insurer” under regulatory law. At the time, under California law, “insurers” were required to pay a gross premiums tax, or GPT, calculated as 	2.35% 	on
gross premiums. As a licensed HCSP, BCC has paid the California Corporate Franchise Tax, or CFT, the tax paid by California businesses generally. Plaintiff
contends that BCC must pay the GPT rather than the CFT, and seeks a writ of mandate directing the taxing agencies to collect the GPT and an order requiring BCC
to pay GPT back taxes, interest, and penalties for the eight-year period prior to the filing of the complaint.
In March 2018, the Superior Court denied BCC’s motion for judgment on the pleadings and similar motions brought by other entities. We filed a writ of
mandate in the California Court of Appeal. Although the California Court of Appeal initially accepted our writ, it later indicated that it would not hear the issues
raised by our writ until the case concludes in the Superior Court. The Superior Court postponed the July 2020 trial date to January 2021. The parties are currently
engaged in discovery. BCC has filed a motion for summary judgment, which is scheduled to be heard in October 2020. Because the GPT is constitutionally
imposed in lieu of certain other taxes, BCC has filed protective tax refund claims with the City of Los Angeles, the California Department of Health Care Services
and the Franchise Tax Board to protect its rights to recover certain taxes previously paid should BCC eventually be determined to be subject to the GPT for the tax
periods at issue in the litigation. BCC intends to vigorously defend this suit; however, its ultimate outcome cannot be presently determined.
Express Scripts, Inc. Pharmacy Benefit Management Litigation
In March 2016, we filed a lawsuit against Express Scripts, Inc., or Express Scripts, our vendor at the time for PBM services, captioned 	Anthem, Inc. v. Express
Scripts, Inc., in the U.S. District Court for the Southern District of New York. The
-29-

-- 33 of 72 --

lawsuit seeks to recover over 	$14,800 	in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties,
or the ESI PBM Agreement, over 	$158 	in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement, including that
Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive
benchmark pricing to us through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM
Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.
Express Scripts has disputed our contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI
PBM Agreement, and (ii) that it has no obligation to ensure that we receive any specific level of pricing, that we have no contractual right to any change in pricing
under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that we
have been unjustly enriched by its payment of 	$4,675 	at the time we entered into the ESI PBM Agreement. In March 2017, the court granted our motion to dismiss
Express Scripts’ counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. The only remaining
claims are for breach of contract and declaratory relief. The period of time for completing discovery has been extended to August 2020 due to the COVID-19
pandemic. We intend to vigorously pursue our claims and defend against any counterclaims, which we believe are without merit; however, the ultimate outcome
cannot be presently determined.
In re Express Scripts/Anthem ERISA Litigation
We are a defendant in a class action lawsuit that was initially filed in June 2016 against Anthem, Inc. and Express Scripts, which has been consolidated into a
single multi-district lawsuit captioned 	In Re Express Scripts/Anthem ERISA Litigation, 	in the U.S. District Court for the Southern District of New York. The
consolidated complaint was filed by plaintiffs against Express Scripts and us on behalf of all persons who are participants in or beneficiaries of any ERISA or non-
ERISA healthcare plan from December 1, 2009 to December 31, 2019 in which we provided prescription drug benefits through the ESI PBM Agreement and paid
a percentage based co-insurance payment in the course of using that prescription drug benefit. The plaintiffs allege that we breached our duties, either under
ERISA or with respect to the implied covenant of good faith and fair dealing implied in the health plans, (i) by failing to adequately monitor Express Scripts’
pricing under the ESI PBM Agreement, (ii) by placing our own pecuniary interest above the best interests of our insureds by allegedly agreeing to higher pricing in
the ESI PBM Agreement in exchange for the purchase price for our NextRx PBM business, and (iii) with respect to the non-ERISA members, by negotiating and
entering into the ESI PBM Agreement that was allegedly detrimental to the interests of such non-ERISA members. Plaintiffs seek to hold us and Express Scripts
jointly and severally liable and to recover all losses suffered by the proposed class, equitable relief, disgorgement of alleged ill-gotten gains, injunctive relief,
attorney’s fees and costs and interest.
In April 2017, we filed a motion to dismiss the claims brought against us, and it was granted, without prejudice, in January 2018. Plaintiffs filed a notice of
appeal with the United States Court of Appeals for the Second Circuit, which was heard in October 2018 but has not yet been decided. We intend to vigorously
defend this suit; however, its ultimate outcome cannot be presently determined.
Cigna Corporation Merger Litigation
In July 2015, we and Cigna Corporation, or Cigna, announced that we entered into the Cigna Agreement and Plan of Merger, or Cigna Merger Agreement,
pursuant to which we would acquire all outstanding shares of Cigna. In July 2016, the U.S. Department of Justice, or DOJ, along with certain state attorneys
general, filed a civil antitrust lawsuit in the U.S. District Court for the District of Columbia, or District Court, seeking to block the merger. In February 2017, Cigna
purported to terminate the Cigna Merger Agreement and commenced litigation against us in the Delaware Court of Chancery, or Delaware Court, seeking
damages, including the 	$1,850 	termination fee pursuant to the terms of the Cigna Merger Agreement, and a declaratory judgment that its purported termination of
the Cigna Merger Agreement was lawful, among other claims, which is captioned 	Cigna Corp. v. Anthem Inc.
Also in February 2017, we initiated our own litigation against Cigna in the Delaware Court seeking a temporary restraining order to enjoin Cigna from
terminating the Cigna Merger Agreement, specific performance compelling Cigna to comply with the Cigna Merger Agreement and damages, which is captioned
Anthem Inc. v. Cigna Corp. In April 2017, the U.S. Circuit Court of Appeals for the District of Columbia affirmed the ruling of the District Court, which blocked
the
-30-

-- 34 of 72 --

merger. In May 2017, after the Delaware Court denied our motion to enjoin Cigna from terminating the Cigna Merger Agreement, we delivered to Cigna a notice
terminating the Cigna Merger Agreement.
In the Delaware Court litigation, trial commenced in late February 2019 and concluded in March 2019. The Delaware Court held closing argument in
November 2019 and took the matter under consideration. In February 2020, the Delaware Court requested supplemental briefing, which has been submitted. We
believe Cigna’s allegations are without merit and we intend to vigorously pursue our claims and defend against Cigna’s allegations; however, the ultimate outcome
of our litigation with Cigna cannot be presently determined.
In October 2018, a shareholder filed a derivative lawsuit in the State of Indiana Marion County Superior Court, captioned 	Henry Bittmann, Derivatively, et al.
v. Joseph R Swedish, et al., purportedly on behalf of us and our shareholders against certain current and former directors and officers alleging breaches of fiduciary
duties, unjust enrichment and corporate waste associated with the Cigna Merger Agreement. This case has been stayed at the request of the parties pending the
outcome of our litigation with Cigna in the Delaware Court. This lawsuit’s ultimate outcome cannot be presently determined.
Medicare Risk Adjustment Litigation
In March 2020, the DOJ filed a civil lawsuit against Anthem, Inc. in the U.S. District Court for the Southern District of New York in a case captioned 	United
States v. Anthem, Inc. The DOJ’s suit alleges, among other things, that we falsely certified the accuracy of the diagnosis data we submitted to the Centers for
Medicare and Medicaid Services, or CMS, for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The
DOJ further alleges that, as a result of these purported acts, we caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information,
which enabled us to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July
2020, alleging the same causes of action but revising some of its allegations. 	We intend to vigorously defend this suit; however, the ultimate outcome cannot be
presently determined.
Investigations of CareMore and HealthSun
With the assistance of outside counsel, we are conducting investigations of risk-adjustment practices (unrelated to our retrospective chart review program) at
CareMore Health Plans, Inc., or CareMore, one of our California subsidiaries and HealthSun Health Plans, Inc., or HealthSun, one of our Florida subsidiaries. Our
CareMore investigation has resulted in the termination of CareMore’s relationship with one contracted provider in California. Our HealthSun investigation focuses
on risk adjustment practices initiated prior to our acquisition of HealthSun in December 2017 that continued after the acquisition. We have voluntarily self-
disclosed the existence of both investigations to CMS and the Criminal Division of the DOJ, which then initiated an investigation. We are cooperating with that
investigation. We have also asserted indemnity claims for escrowed funds under the HealthSun purchase agreement for, among other things, breach of healthcare
representation provisions, based on the conduct discovered during our investigation. We are in active litigation with one group of sellers regarding part of the
escrowed funds in a case captioned 	LPPAS Representative, LLC v. ATH Holding Company, LLC 	in the Delaware Court.
Cyber Attack Regulatory Proceedings and Litigation
In February 2015, we reported that we were the target of a sophisticated external cyber attack during which the attackers gained unauthorized access to certain
of our information technology systems and obtained personal information related to many individuals and employees. To date, there is no evidence that credit card
or medical information was accessed or obtained. Upon discovery of the cyber attack, we took immediate action to remediate the security vulnerability and have
continued to implement security enhancements since this incident.
Federal and state agencies are investigating, or have investigated, events related to the cyber attack, including how it occurred, its consequences and our
responses. The investigations have all been resolved with the exception of an ongoing investigation by a multi-state group of attorneys general, which remains
outstanding. Although we are cooperating in this investigation, we may be subject to additional fines or other obligations. We intend to vigorously defend the
remaining regulatory investigation; however, its ultimate outcome cannot be presently determined.
-31-

-- 35 of 72 --

We have contingency plans and insurance coverage for certain expenses and potential liabilities of this nature and will pursue coverage for all applicable
losses; however, the ultimate outcome of our pursuit of insurance coverage cannot be presently determined.
Other Contingencies
From time to time, we and certain of our subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the
ordinary course of business. We, like HMOs and health insurers generally, exclude certain healthcare and other services from coverage under our HMO, PPO and
other plans. We are, in the ordinary course of business, subject to the claims of our enrollees arising out of decisions to restrict or deny reimbursement for
uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on us. In addition, the
risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.
In addition to the lawsuits described above, we are also involved in other pending and threatened litigation of the character incidental to our business, and are
from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews
and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and
subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines,
penalties, other sanctions and additional rules, regulations or other restrictions on our business operations. Any liability that may result from any one of these
actions, or in the aggregate, could have a material adverse effect on our consolidated financial position or results of operations.
Contractual Obligations and Commitments
In March 2020, we entered into an agreement with a vendor for information technology infrastructure and related management and support services through
June 2025. The new agreement supersedes certain prior agreements for such services and includes provisions for additional services not provided under those
agreements. Our aggregate commitment under this agreement is approximately 	$1,700. We will have the ability to terminate the agreement upon the occurrence of
certain events, subject to early termination fees.
In the second quarter of 2019, we began using our new pharmacy benefits manager named IngenioRx, Inc., or IngenioRx, to market and offer PBM services to
fully-insured and self-funded Anthem health plan customers, as well as to external customers outside of the health plans we own. The comprehensive prescription
benefits management services portfolio includes, but is not limited to, formulary management, pharmacy networks, prescription drug database, member services
and mail order capabilities. Also in the second quarter of 2019, IngenioRx began delegating certain PBM administrative functions, such as claims processing and
prescription fulfillment, to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With IngenioRx, we
retain the responsibilities for clinical and formulary strategy and development, member and employer experiences, operations, sales, marketing, account
management and retail network strategy. From December 2009 through December 2019, we delegated certain PBM functions and administrative services to
Express Scripts pursuant to the ESI PBM Agreement. In January 2019, we exercised our contractual right to terminate the ESI PBM Agreement earlier than the
original expiration date of December 31, 2019, due to the acquisition of Express Scripts by Cigna. We began transitioning existing members from Express Scripts
to IngenioRx in the second quarter of 2019, and completed the transition of all of our members by January 1, 2020. Prior to the termination of the ESI PBM
Agreement, Express Scripts managed the network of pharmacy providers, operated mail order pharmacies and processed prescription drug claims on our behalf,
while we sold and supported the product for our members, made formulary decisions, sold drug benefit design strategy and provided front line member
support. Express Scripts continues to provide certain audit and run out transition services related to our PBM business. Notwithstanding our termination of the ESI
PBM Agreement, the litigation between us and Express Scripts regarding the ESI PBM Agreement continues. For additional information regarding this lawsuit,
refer to the 	Litigation and Regulatory Proceedings–Express Scripts, Inc. Pharmacy Benefit Management Litigation 	section above. We believe we have
appropriately recognized all rights and obligations under the ESI PBM Agreement as of June 30, 2020.
-32-

-- 36 of 72 --

12. 	Capital Stock
Use of Capital – Dividends and Stock Repurchase Program
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The
declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial
condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
A summary of our cash dividend activity for the 	six months ended June 30, 2020 	and 	2019 	is as follows:
Declaration Date 	Record Date 	Payment Date
Cash
Dividend
per Share 	Total
Six Months Ended June 30, 2020
January 28, 2020 	March 16, 2020 	March 27, 2020 	$0.95 	$ 	240
April 28, 2020 	June 10, 2020 	June 25, 2020 	$0.95 	$ 	242
Six Months Ended June 30, 2019
January 29, 2019 	March 18, 2019 	March 29, 2019 	$0.80 	$ 	206
April 23, 2019 	June 10, 2019 	June 25, 2019 	$0.80 	$ 	206
On July 28, 2020, our Audit Committee declared a third quarter 2020 dividend to shareholders of 	$0.95 	per share, payable on 	September 25, 2020 	to
shareholders of record at the close of business on 	September 10, 2020.
Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On December 7, 2017, the Board of Directors authorized a
$5,000 	increase to the common stock repurchase program. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions
on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share
repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase
program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of
capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings. We temporarily
suspended our share repurchase program in March 2020 as a precautionary measure in light of the COVID-19 pandemic, but resumed in late June 2020 after
market conditions improved.
A summary of common stock repurchases for the 	six months ended June 30, 2020 	and 	2019 	is as follows:
Six Months Ended June 30
2020 	2019
Shares repurchased 	2.1 	2.8
Average price per share 	$ 	273.72 	$ 	273.84
Aggregate cost 	$ 	584 	$ 	752
Authorization remaining at the end of the period 	$ 	3,208 	$ 	4,741
For additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt”, included in this Form 10-Q and Note 12, “Debt,” to
our audited consolidated financial statements as of and for the year ended 	December 31, 2019 	included in our 	2019 	Annual Report on Form 10-K.
-33-

-- 37 of 72 --

Stock Incentive Plans
A summary of stock option activity for the 	six months ended June 30, 2020 	is as follows:
Number of
Shares
Weighted-
Average
Option Price
per Share
Weighted-
Average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
Outstanding at January 1, 2020 	3.1 	$ 	190.31
Granted 	1.0 	271.33
Exercised 	(0.5) 	118.84
Forfeited or expired 	(0.1) 	267.09
Outstanding at June 30, 2020 	3.5 	221.84 	7.08 	$ 	182
Exercisable at June 30, 2020 	1.9 	176.59 	5.51 	$ 	175
A summary of the nonvested restricted stock activity, including restricted stock units, for the 	six months ended June 30, 2020 	is as follows:
Restricted
Stock Shares
and Units
Weighted-
Average
Grant Date
Fair Value
per Share
Nonvested at January 1, 2020 	1.4 	$ 	242.47
Granted 	1.3 	272.14
Vested 	(1.2) 	193.36
Forfeited 	(0.1) 	269.70
Nonvested at June 30, 2020 	1.4 	271.77
During the 	six months ended June 30, 2020, we granted approximately 	0.2 	restricted stock units that are contingent upon us achieving earnings targets over the
three year period from 2020 to 2022. These grants have been included in the activity shown above, but will be subject to adjustment at the end of 2022 based on
results in the three year period.
During the 	six months ended June 30, 2020, we granted an additional 	0.6 	restricted stock units associated with our 2017 grants that were earned as a result of
satisfactory completion of performance measures between 2017 and 2019. These grants and vested shares have been included in the activity shown above.
Fair Value
We use a binomial lattice valuation model to estimate the fair value of all stock options granted. For a more detailed discussion of our stock incentive plan fair
value methodology, see Note 14, “Capital Stock,” to our audited consolidated financial statements as of and for the year ended 	December 31, 2019 	included in our
2019 	Annual Report on Form 10-K.
The following weighted-average assumptions were used to estimate the fair values of options granted during the 	six months ended June 30, 2020 	and 	2019:
Six Months Ended June 30
2020 	2019
Risk-free interest rate 	1.30% 	2.69%
Volatility factor 	26.00% 	25.00%
Quarterly dividend yield 	0.350% 	0.260%
Weighted-average expected life (years) 	4.30 	4.40
-34-

-- 38 of 72 --

The following weighted-average fair values per option or share were determined for the 	six months ended June 30, 2020 	and 	2019:
Six Months Ended June 30
2020 	2019
Options granted during the period 	$ 	54.04 	$ 	68.80
Restricted stock awards granted during the period 	272.14 	307.08
13. 	Accumulated Other Comprehensive Loss
A reconciliation of the components of accumulated other comprehensive loss at 	June 30, 2020 	and 	2019 	is as follows:
June 30
2020 	2019
Investments:
Gross unrealized gains 	$ 	974 	$ 	626
Gross unrealized losses 	(229) 	(60)
Net pre-tax unrealized gains 	745 	566
Deferred tax liability 	(183) 	(130)
Net unrealized gains on investments 	562 	436
Non-credit components of impairments on investments:
Unrealized losses 	(32) 	(4)
Deferred tax asset 	8 	1
Net unrealized non-credit component of impairments on investments 	(24) 	(3)
Cash flow hedges:
Gross unrealized losses 	(323) 	(308)
Deferred tax asset 	67 	65
Net unrealized losses on cash flow hedges 	(256) 	(243)
Defined benefit pension plans:
Deferred net actuarial loss 	(707) 	(738)
Deferred prior service credits 	(1) 	(1)
Deferred tax asset 	181 	190
Net unrecognized periodic benefit costs for defined benefit pension plans 	(527) 	(549)
Postretirement benefit plans:
Deferred net actuarial loss 	(25) 	(57)
Deferred prior service costs 	16 	28
Deferred tax asset 	2 	7
Net unrecognized periodic benefit costs for postretirement benefit plans 	(7) 	(22)
Foreign currency translation adjustments:
Gross unrealized losses 	(3) 	(3)
Deferred tax asset 	1 	1
Net unrealized losses on foreign currency translation adjustments 	(2) 	(2)
Accumulated other comprehensive loss 	$ 	(254) 	$ 	(383)
-35-

-- 39 of 72 --

Other comprehensive income (loss) reclassification adjustments for the three months ended 	June 30, 2020 	and 	2019 	are as follows:
Three Months Ended June 30
2020 	2019
Investments:
Net holding gain on investment securities arising during the period, net of tax expense of ($238) and ($71),
respectively 	$ 	741 	$ 	237
Reclassification adjustment for net realized (gain) loss on investment securities, net of tax expense (benefit) of $4
and ($1), respectively 	(11) 	1
Total reclassification adjustment on investments 	730 	238
Non-credit component of impairments on investments:
Non-credit component of impairments on investments, net of tax expense of ($2) and ($0), respectively 	10 	(1)
Cash flow hedges:
Holding gain, net of tax expense of ($1) and ($0), respectively 	3 	—
Other:
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, net
of tax expense of ($4) and ($1), respectively 	10 	3
Foreign currency translation adjustment, net of tax expense of ($0) and ($0), respectively 	1 	—
Net gain recognized in other comprehensive income, net of tax expense of ($241) and ($73), respectively 	$ 	754 	$ 	240
Other comprehensive income (loss) reclassification adjustments for the 	six 	months ended 	June 30, 2020 	and 	2019 	are as follows:
Six Months Ended June 30
2020 	2019
Investments:
Net holding gain on investment securities arising during the period, net of tax expense of ($23) and ($170),
respectively 	$ 	33 	$ 	586
Reclassification adjustment for net realized loss on investment securities, net of tax benefit of ($5) and ($2),
respectively 	8 	9
Total reclassification adjustment on investments 	41 	595
Non-credit component of impairments on investments:
Non-credit component of impairments on investments, net of tax benefit of $7 and $0, respectively 	(22) 	(1)
Cash flow hedges:
Holding gain, net of tax expense of ($2) and ($0), respectively 	6 	3
Other:
Net change in unrecognized periodic benefit costs for defined benefit pension and postretirement benefit plans, net
of tax expense of ($7) and ($2), respectively 	17 	6
Net gain recognized in other comprehensive income, net of tax expense of ($30) and ($174), respectively 	$ 	42 	$ 	603
-36-

-- 40 of 72 --

14. 	Earnings per Share
The denominator for basic and diluted earnings per share for the 	three and six 	months ended 	June 30, 2020 	and 	2019 	is as follows:
Three Months Ended
June 30
Six Months Ended
June 30
2020 	2019 	2020 	2019
Denominator for basic earnings per share – weighted-average shares 	252.2 	256.7 	252.3 	256.9
Effect of dilutive securities – employee stock options, nonvested restricted stock awards and
convertible debentures 	3.2 	4.3 	3.6 	4.7
Denominator for diluted earnings per share 	255.4 	261.0 	255.9 	261.6
During the three months ended 	June 30, 2020 	and 	2019, weighted-average shares related to certain stock options of 	1.6 	and 	0.7, respectively, were excluded
from the denominator for diluted earnings per share because the stock options were anti-dilutive. During the 	six 	months ended 	June 30, 2020 	and 	2019, weighted-
average shares related to certain stock options of 	1.3 	and 	0.5, respectively, were excluded from the denominator for diluted earnings per share because the stock
options were anti-dilutive.
During the three and 	six months ended June 30, 2020, we issued approximately 	0.1 	and 	1.3 	restricted stock units under our stock incentive plans, 	0.2 	of which
vesting is contingent upon us meeting specified annual earnings targets for the three year period of 	2020 	through 2022. During the three and 	six months ended
June 30, 2019, we issued approximately 	0.0 	and 	0.5 	restricted stock units under our stock incentive plans, 	0.2 	of which vesting is contingent upon us meeting
specified annual earnings targets for the three year period of 2019 through 2021. The contingent restricted stock units have been excluded from the denominator for
diluted earnings per share and will be included only if and when the contingency is met.
15. 	Segment Information
The results of our operations are now described through 	four 	reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and
Other.
Our Commercial & Specialty Business segment includes our Local Group, National Accounts, Individual and Specialty businesses. Business units in the
Commercial & Specialty Business segment offer fully-insured health products; provide a broad array of managed care services to self-funded customers including
claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness
programs and other administrative services; and provide an array of specialty and other insurance products and services such as dental, vision, life and disability
insurance benefits.
Our Government Business segment includes our Medicare and Medicaid businesses, National Government Services, or NGS, and services provided to the
federal government in connection with the FEHB program. Our Medicare business includes services such as Medicare Supplement plans; Medicare Advantage,
including Special Needs Plans; Medicare Part D; and dual-eligible programs through Medicare-Medicaid Plans. Our Medicaid business includes our managed care
alternatives through publicly funded healthcare programs, including Medicaid, Medicaid expansion programs related to the Patient Protection and Affordable Care
Act and the Health Care and Education Reconciliation Act of 2010, as amended, Temporary Assistance for Needy Families, programs for seniors and people with
disabilities, Children’s Health Insurance Programs, and specialty programs such as those focused on long-term services and support, HIV/AIDS, foster care,
behavioral health and/or substance abuse disorders, and intellectual disabilities or developmental disabilities. NGS acts as a Medicare contractor for the federal
government in several regions across the nation.
Our IngenioRx segment includes our PBM business, which began its operations during the second quarter of 2019. IngenioRx markets and offers PBM
services to fully-insured and self-funded Anthem health plan customers, as well as to external customers outside of the health plans we own. IngenioRx has a
comprehensive PBM services portfolio, which includes services such as formulary management, pharmacy networks, prescription drug database, member services
and mail order capabilities. In 2019, IngenioRx was included in our Other reportable segment. Beginning in 2020, IngenioRx meets
-37-

-- 41 of 72 --

the quantitative thresholds for a reportable segment based on the FASB guidance. Amounts for the three and six months ended June 30, 2019 have been
reclassified to conform to the current year presentation for comparability.
Our Other segment includes our Diversified Business Group, or DBG, which is our integrated health services business, and certain eliminations and corporate
expenses not allocated to our other reportable segments. We reclassified DBG from our Government Business segment to the Other segment during the second
quarter of 2019 to reflect changes in how our segments are being managed. Also, beginning on February 28, 2020, DBG includes Beacon.
For our 2019 segment reporting, operating gains (losses) generated from IngenioRx and DBG affiliated activity were included in our Commercial & Specialty
Business and Government Business segments based upon their utilization of services from IngenioRx and DBG, which aligns with the method by which we
assessed the 2019 operating performance of our reportable segments. 	Beginning January 1, 2020, we are managing the operating performance of each of our
segments on a standalone basis.
Affiliated revenues represent revenues or cost for services provided by IngenioRx and DBG to our subsidiaries, are recorded at cost or management’s estimate
of fair market value, and are eliminated in consolidation.
Financial data by reportable segment for the 	three and six 	months ended 	June 30, 2020 	and 	2019 	is as follows:
Commercial
& Specialty
Business
Government
Business 	IngenioRx 	Other 	Eliminations 	Total
Three Months Ended June 30, 2020
Operating revenue - unaffiliated 	$ 	8,789 	$ 	17,242 	$ 	2,544 	$ 	603 	$ 	— 	$ 	29,178
Operating revenue - affiliated 	— 	— 	2,725 	849 	(3,574) 	—
Operating gain 	1,372 	1,618 	304 	66 	— 	3,360
Three Months Ended June 30, 2019
Operating revenue - unaffiliated 	$ 	9,417 	$ 	15,538 	$ 	145 	$ 	77 	$ 	— 	$ 	25,177
Operating revenue - affiliated 	— 	— 	103 	469 	(572) 	—
Operating gain (loss) 	983 	480 	— 	(30) 	— 	1,433
Six Months Ended June 30, 2020
Operating revenue - unaffiliated 	$ 	18,150 	$ 	34,708 	$ 	4,887 	$ 	881 	$ 	— 	$ 	58,626
Operating revenue - affiliated 	— 	— 	5,579 	1,598 	(7,177) 	—
Operating gain 	2,792 	2,029 	653 	80 	— 	5,554
Six Months Ended June 30, 2019
Operating revenue - unaffiliated 	$ 	18,809 	$ 	30,464 	$ 	145 	$ 	147 	$ 	— 	$ 	49,565
Operating revenue - affiliated 	— 	— 	103 	947 	(1,050) 	—
Operating gain (loss) 	2,581 	854 	— 	(62) 	— 	3,373
-38-

-- 42 of 72 --

The major product revenues for each of the reportable segments for the 	three and six 	months ended 	June 30, 2020 	and 	2019 	are as follows:
Three Months Ended
June 30
Six Months Ended
June 30
2020 	2019 	2020 	2019
Commercial & Specialty Business
Managed care products 	$ 	7,132 	$ 	7,646 	$ 	14,700 	$ 	15,264
Managed care services 	1,263 	1,353 	2,645 	2,719
Dental/Vision products and services 	284 	327 	599 	650
Other 	110 	91 	206 	176
Total Commercial & Specialty Business 	8,789 	9,417 	18,150 	18,809
Government Business
Managed care products 	17,149 	15,444 	34,524 	30,264
Managed care services 	93 	94 	184 	200
Total Government Business 	17,242 	15,538 	34,708 	30,464
IngenioRx
Pharmacy products and services 	5,269 	248 	10,466 	248
Total IngenioRx 	5,269 	248 	10,466 	248
Other
Other 	1,452 	546 	2,479 	1,094
Eliminations
Eliminations 	(3,574) 	(572) 	(7,177) 	(1,050)
Total product revenues 	$ 	29,178 	$ 	25,177 	$ 	58,626 	$ 	49,565
The classification between managed care products and managed care services in the above table primarily distinguishes between the levels of risk assumed.
Managed care products represent insurance products where we bear the insurance risk, whereas managed care services represent product offerings where we
provide claims adjudication and other administrative services to the customer, but the customer principally bears the insurance risk.
A reconciliation of reportable segments’ operating revenue to the amounts of total revenues included in our consolidated statements of income for the 	three
and six 	months ended 	June 30, 2020 	and 	2019 	is as follows:
Three Months Ended
June 30
Six Months Ended
June 30
2020 	2019 	2020 	2019
Reportable segments’ operating revenue 	$ 	29,178 	$ 	25,177 	$ 	58,626 	$ 	49,565
Net investment income 	57 	285 	311 	495
Net realized gains (losses) on financial instruments 	18 	11 	(6) 	89
Impairment recoveries (losses) recognized in income 	11 	(7) 	(46) 	(17)
Total revenues 	$ 	29,264 	$ 	25,466 	$ 	58,885 	$ 	50,132
-39-

-- 43 of 72 --

A reconciliation of reportable segments’ operating gain to income before income tax expense included in our consolidated statements of income for the 	three
and six 	months ended 	June 30, 2020 	and 	2019 	is as follows:
Three Months Ended
June 30
Six Months Ended
June 30
2020 	2019 	2020 	2019
Reportable segments’ operating gain 	$ 	3,360 	$ 	1,433 	$ 	5,554 	$ 	3,373
Net investment income 	57 	285 	311 	495
Net realized gains (losses) on financial instruments 	18 	11 	(6) 	89
Impairment recoveries (losses) recognized in income 	11 	(7) 	(46) 	(17)
Interest expense 	(201) 	(184) 	(395) 	(371)
Amortization of other intangible assets 	(93) 	(85) 	(176) 	(172)
(Loss) gain on extinguishment of debt 	(3) 	— 	(4) 	1
Income before income tax expense 	$ 	3,149 	$ 	1,453 	$ 	5,238 	$ 	3,398
16. 	Leases
We lease office space and certain computer and related equipment using noncancelable operating leases. Our leases have remaining lease terms of 	1 	year to 	12
years.
The information related to our leases is as follows:
Balance Sheet Location 	June 30, 2020 	December 31, 2019
Operating Leases
Right-of-use assets 	Other noncurrent assets 	$ 	917 	$ 	575
Lease liabilities, current 	Other current liabilities 	193 	158
Lease liabilities, noncurrent 	Other noncurrent liabilities 	815 	482
Three Months Ended
June 30
Six Months Ended
June 30
2020 	2019 	2020 	2019
Lease Expense
Operating lease expense 	$ 	59 	$ 	45 	$ 	106 	$ 	90
Short-term lease expense 	14 	12 	27 	24
Sublease income 	(4) 	(4) 	(7) 	(8)
Total lease expense 	$ 	69 	$ 	53 	$ 	126 	$ 	106
Other information
Operating cash paid for amounts included in the measurement of lease liabilities,
operating leases 	$ 	46 	$ 	44 	$ 	90 	$ 	89
Right-of-use assets obtained in exchange for new lease liabilities, operating leases 	$ 	33 	$ 	— 	$ 	356 	$ 	—
Weighted average remaining lease term, operating leases 	7 years 	7 years 	7 years 	7 years
Weighted average discount rate, operating leases 	3.45% 	3.90% 	3.45% 	3.90%
-40-

-- 44 of 72 --

At 	June 30, 2020, future lease payments for noncancellable operating leases with initial or remaining terms of one year or more are as follows:
2020 (excluding the six months ended June 30, 2020) 	$ 	99
2021 	192
2022 	176
2023 	153
2024 	123
Thereafter 	313
Total future minimum payments 	1,056
Less imputed interest 	(48)
Total lease liabilities 	$ 	1,008
As of 	June 30, 2020, we have additional operating leases for building spaces that have not yet commenced, and some building spaces are being constructed by
the lessors and their agents. These leases have terms of up to 	12 	years and 	are expected to commence on various dates during 2020 and 2021 when the construction
is complete and we take possession of the buildings. The undiscounted lease payments for these leases, which are not included in the tables above, aggregate 	$138.
-41-

-- 45 of 72 --

ITEM 2. 	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
(In Millions, Except Per Share Data or as Otherwise Stated Herein)
This Management’s Discussion and Analysis of Financial Condition and Results of Operations, or MD&A, should be read in conjunction with the
accompanying consolidated financial statements and notes, our consolidated financial statements and notes as of and for the year ended December 31, 2019 and the
MD&A included in our 2019 Annual Report on Form 10-K. References to the terms “we,” “our,” “us,” or “Anthem” used throughout this MD&A refer to Anthem,
Inc., an Indiana corporation, and unless the context otherwise requires, its direct and indirect subsidiaries. References to the “states” include the District of
Columbia, unless the context otherwise requires.
Results of operations, cost of care trends, investment yields and other measures for the 	three and six 	months ended 	June 30, 2020 	are not necessarily indicative
of the results and trends that may be expected for the full year ending 	December 31, 2020, or any other period.
Overview
We are one of the largest health benefits companies in the United States in terms of medical membership, serving greater than 	42 	million 	medical members
through our affiliated health plans as of 	June 30, 2020. 	We serve our members as the Blue Cross licensee for California and as the Blue Cross and Blue Shield, or
BCBS, licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 	30 	counties in the Kansas City area), Nevada, New
Hampshire, New York (in the New York City metropolitan area and upstate New York), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington,
D.C.) and Wisconsin. In a majority of these service areas, we do business as Anthem Blue Cross, Anthem Blue Cross and Blue Shield, and Empire Blue Cross
Blue Shield or Empire Blue Cross. We also conduct business through arrangements with other BCBS licensees as well as other strategic partners. Through our
subsidiaries, we also serve customers in numerous 	states across the country as AIM Specialty Health, Amerigroup, Aspire Health, Beacon, CareMore, Freedom
Health, HealthLink, HealthSun, Optimum HealthCare, Simply Healthcare, and/or Unicare. Also, in the second quarter of 2019, we began providing 	pharmacy
benefits management, or PBM, services through our IngenioRx subsidiary. We are licensed to conduct insurance operations in all 50 states and the District of
Columbia through our subsidiaries.
For additional information about our organization, see Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” included in our 2019 Annual Report on Form 10-K. Additional information on our segments can be found in this MD&A
and in Note 15, “Segment Information” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
COVID-19
In March 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus, or COVID-19, a global health pandemic and
recommended containment and mitigation measures worldwide. The COVID-19 outbreak has also been declared a national emergency in the United States and
continues to spread domestically and in other countries globally. To mitigate the spread of this virus, beginning in March 2020 most states imposed shelter-in-place
or stay-at-home orders, which generally required businesses not considered essential to close their physical offices. While these orders have largely been lifted,
many states and local authorities continue to impose certain restrictions on the conduct of businesses and individuals. The virus and efforts to prevent its spread
have drastically impacted the global economy, causing market instability and increasing unemployment in the United States.
In response to the COVID-19 pandemic, federal and state legislation has been, and we expect will continue to be, enacted that will impact our business. For
additional information on existing legislation related to the impact of the COVID-19 pandemic on our business, see “Regulatory Trends and Uncertainties” in this
MD&A.
As COVID-19 continues to spread, we remain focused on increasing access and coverage for our members, adapting tools and policies to assist consumers and
care providers, and leveraging data and advanced analytics to provide innovative solutions. We launched an online COVID-19 assessment tool and enhanced the
digital capabilities of Sydney Care, our mobile app, to include a symptom checker feature, as well as virtual text visit and video visit features. The symptom
checker feature guides users through a resulting action plan depending upon the results of the user’s assessment, and the virtual text
-42-

-- 46 of 72 --

feature connects users to certified physicians who can provide medical care, including prescribing medication and ordering lab work during consults as necessary.
Through at least September 30, 2020, we are providing expanded telehealth coverage including for mental health as well as some physical, occupational and
speech therapy, and are continuing to waive cost shares for in-network telehealth visits, including telephonic visits and those for mental health, for our members in
fully-insured employer plans, Individual plans, Medicare plans and Medicaid plans, where permissible.
We also introduced a suite of digital tools, including C19 Navigator and C19 Explorer, through our online portal and mobile apps. C19 Navigator is a
dashboard solution designed for our employer customers and provides member data and updates related to COVID-19. C19 Explorer aggregates real-time COVID-
19 data to present trends and predictions for our communities and is designed to support public health officials, business leaders and consumers so they can make
informed, data-driven decisions during this pandemic. The other digital tools are available to help individuals with mental health support or emergency services
such as finding assistance with food, transportation, and childcare.
We made other changes to our membership benefits and business operations in response to the COVID-19 pandemic and may make additional changes in the
future. We relaxed early prescription refill policies for maintenance and specialty medications and are encouraging the use of home delivery services to ensure
access to necessary medications. We are waiving cost sharing for in-network COVID-19 diagnostic tests and treatment through December 31, 2020 for members
enrolled in our fully-insured employer plans, Individual plans and Medicare Advantage plans. Self-insured employers who previously chose to adopt cost sharing
waivers for treatment can choose to extend the waivers through the end of 2020. Further, we are providing a one-time premium credit to members enrolled in select
Individual plans and fully-insured employer customers. In addition, individuals in stand-alone and group dental plans will also receive a one-time credit. Future
regulatory action could require us to provide additional coverage or credits related to COVID-19 treatments.
We are also providing support to care provider partners of our affiliated health plans that is designed to help them continue to focus on caring for patients,
including funding to support telehealth capabilities, quality-based programs and personal protective equipment, or PPE, and extending financial assistance to
targeted independent primary care physician organizations and multispecialty groups who are facing financial pressure during this crisis. Additionally, we are
actively working with care providers to accelerate claims processing for outstanding accounts receivables, resolving claims where possible and appropriate, as well
as accelerating payments to support state-specific Medicaid programs. We are simplifying access to care by temporarily suspending select prior authorization
requirements for respiratory services and medical equipment critical to COVID-19 treatment and temporarily extending prior authorizations on elective inpatient
and outpatient procedures issued before May 30, 2020. We are also providing in-network dental providers a PPE Credit per patient, per visit, from June 15, 2020
through the end of August 2020.
The safety, health and wellbeing of our employees remains a top priority as we face these challenges together and continue our work in support of those we
serve. To protect our employees and mitigate the spread of COVID-19, we implemented travel limitations and introduced workplace modifications consistent with
the Centers for Disease Control and Prevention guidelines and social distancing protocols. We are gradually reopening our offices in accordance with local
guidelines; however, the majority of our workforce continues to work remotely. In addition to transitioning to a remote work environment, we expanded our
employee benefits to provide additional support, including up to 80 hours of paid emergency leave if employees are experiencing symptoms of COVID-19 or
caring for young children whose schools have been closed. We also expanded the use of sick time to include caregiving related to COVID-19 and provided a one-
time premium credit to our covered associates.
With many individuals and families impacted by the COVID-19 pandemic in a variety ways, we remain committed to lifting up our local communities through
a variety of partnership and relief efforts. For example, during the second quarter of 2020, we contributed $50 million to the Anthem Foundation to support its
COVID-19 response and recovery efforts, such as emergency response, food insecurity, mental health and care provider safety resources.
To address food insecurity and other needs for the most vulnerable, our affiliated health plans are reaching out to Medicaid beneficiaries to facilitate
connections with state and social services, that can enroll, or help in enrolling, newly eligible and at-risk members in the Supplemental Nutrition Assistance
Program and Special Supplemental Nutrition Program for Women, Infants, and Children. Our affiliated health plans are also directly contacting Medicare
Advantage and Medicaid consumers to help them make sure they have necessary medications on hand, their nutritional needs are being met and critical health
needs are being addressed during this time of social distancing and isolation.
-43-

-- 47 of 72 --

To date, the COVID-19 pandemic has not had a material adverse impact on our business, cash flows, financial condition or results of operations. However, the
COVID-19 pandemic is evolving and its impact will depend on future developments, which are highly uncertain and cannot be predicted at this time. As such, the
COVID-19 pandemic, including the changes we make in response to it and any further steps taken to expand or otherwise modify the services delivered to our
members, could have a material adverse impact on our business, cash flows, financial condition and results of operations going forward. These impacts include, but
are not limited to, the following:
◦ 	Our covered medical expenses, including preventive care and COVID-19 treatment, may rise;
◦ 	Our membership may decline;
◦ 	Our membership mix may change to less profitable lines of business;
◦ 	Premium receipts from our Commercial and Government customers may be delayed or uncollectable;
◦ 	Reimbursements for benefit payments made on behalf of our self-insured customers may be delayed or uncollectable;
◦ 	Our suppliers’ operations may be interrupted;
◦ 	Our operations may be interrupted;
◦ 	Our access to credit to meet liquidity may become limited and our credit rating may be negatively impacted; and
◦ 	Our investment returns may be reduced and investment values may become impaired.
We are focused on continuing to navigate these challenges and taking measures to address the impacts of the COVID-19 pandemic. To preserve our liquidity
and enhance financial flexibility, we are delaying certain tax payments as permitted by the Internal Revenue Service and the Coronavirus Aid, Relief, and
Economic Security, or CARES, Act and are monitoring our discretionary spending.
We will continue to monitor the COVID-19 pandemic as well as resulting legislative and regulatory changes that may impact our business. For additional
discussion regarding our risk factors, see Part I, Item 1A, “Risk Factors” included in our 2019 Annual Report on Form 10-K and Part II, Item 1A, “Risk Factors”
included in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020.
Business Trends
The Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended, or collectively, the ACA, has
changed and may continue to make broad-based changes to the U.S. healthcare system. We expect the ACA will continue to impact our business model and
strategy. Also, the legal challenges regarding the ACA, including a federal district court decision invalidating the ACA, or the 2018 ACA Decision, which
judgment has been stayed pending appeal, could significantly disrupt our business. During 2019, we modestly expanded our participation in the Individual ACA-
compliant market. Our strategy has been, and will continue to be, to only participate in rating regions where we have an appropriate level of confidence that these
markets are on a path toward sustainability, including, but not limited to, factors such as expected financial performance, regulatory environment, and underlying
market characteristics. We currently offer Individual ACA-compliant products in 91 of the 143 rating regions in which we operate. In addition, the continuing
growth in our government-sponsored business exposes us to increased regulatory oversight.
In the second quarter of 2019, we began using IngenioRx to market and offer PBM services to Anthem health plan customers throughout the country, as well
as to external customers outside of the health plans we own. Our comprehensive PBM services portfolio includes services such as formulary management,
pharmacy networks, prescription drug database, member services and mail order capabilities. In July 2019, we announced our first contract win with a third-party
health insurer, Blue Cross of Idaho, and IngenioRx began providing PBM services under that contract on January 1, 2020. Also in the second quarter of 2019,
IngenioRx began delegating certain PBM administrative functions, such as claims processing and prescription fulfillment, to CaremarkPCS Health, L.L.C., which
is a subsidiary of CVS Health Corporation, pursuant to a five-year agreement. With IngenioRx, we retain the responsibilities for clinical and formulary strategy and
development, member and employer experiences, operations, sales, marketing, account management and retail network strategy. From December 2009 through
December 2019, we delegated certain PBM functions and administrative services to Express Scripts Inc., or Express Scripts, pursuant to our PBM agreement with
Express Scripts, or the ESI PBM Agreement. We began transitioning existing members from Express Scripts to IngenioRx in the second quarter of 2019, and
completed the transition of all of our members by January 1, 2020. We expect IngenioRx to provide our members with more cost-effective solutions and improve
our ability to integrate pharmacy benefits within our medical and specialty platform.
-44-

-- 48 of 72 --

Pricing Trends: 	We strive to price our healthcare benefit products consistent with anticipated underlying medical cost trends. We continue to closely monitor the
COVID-19 pandemic and the impacts it may have on our pricing, such as continued deferral of non-emergent or elective health services, surges in COVID-19
related hospitalizations, and the cost of a potential COVID-19 vaccine. We frequently make adjustments to respond to legislative and regulatory changes as well as
pricing and other actions taken by existing competitors and new market entrants. Product pricing in our Commercial & Specialty Business segment, including our
Individual and Small Group lines of business, remains competitive. Revenues from the Medicare and Medicaid programs are dependent, in whole or in part, upon
annual funding from the federal government and/or applicable state governments. The ACA imposed an annual Health Insurance Provider Fee, or HIP Fee, on
health insurers that write certain types of health insurance on U.S. risks. We price our affected products to cover the impact of the HIP Fee, when applicable. The
HIP Fee was suspended for 2019, has resumed for 2020 and has been permanently eliminated effective in 2021.
Medical Cost Trends: 	Our medical cost trends are primarily driven by increases in the utilization of services across all provider types and the unit cost increases of
these services. We work to mitigate these trends through various medical management programs such as utilization management, condition management, program
integrity and specialty pharmacy management, as well as benefit design changes. There are many drivers of medical cost trends that can cause variance from our
estimates, such as changes in the level and mix of services utilized, regulatory changes, aging of the population, health status and other demographic characteristics
of our members, epidemics, pandemics, advances in medical technology, new high cost prescription drugs, and healthcare provider or member fraud. Our
underlying Local Group medical cost trends reflect the “allowed amount,” or contractual rate, paid to providers. The COVID-19 pandemic has caused, and may
continue to cause, deferral of non-emergent or elective health services, which has decreased our claim costs in the short-term and could increase our claim costs in
the long-term and affect our medical cost trends. Further, the cost and volume of covered services related to the COVID-19 disease could have a material adverse
effect on our claim costs. In response to the current crisis, we expanded coverage for certain members in our affiliated health plans for testing and treatment related
to a COVID-19 diagnosis through December 31, 2020. Governmental action has required us to provide full coverage for COVID-19 testing to our members, and
future governmental action could require us to provide additional coverage. We continue to closely monitor the COVID-19 pandemic and its impacts to our
business, financial condition, results of operations and medical cost trend.
For additional discussion regarding business trends, see Part I, Item 1, “Business” included in our 2019 Annual Report on Form 10-K.
Regulatory Trends and Uncertainties
Federal and state legislation has been enacted, and is likely to continue to be enacted, in response to the COVID-19 pandemic that has had, and we expect will
continue to have, a significant impact on all of our lines of business, including mandates to waive cost-sharing on COVID-19 testing and related services. The
federal government enacted the Coronavirus Preparedness and Response Supplemental Appropriations Act, the Families First Coronavirus Response Act and the
CARES Act in March 2020 and the Paycheck Protection Program and Health Care Enhancement Act in April 2020. These acts provide, among other things,
prohibitions on prior authorization and cost-sharing for certain items and services related to COVID-19 tests, reforms including waiving Medicare originating site
restrictions for qualified providers providing telehealth services, financial support to health care providers, including expansion of the Medicare accelerated
payment program to all providers receiving Medicare payments, and funding to replenish and administer small business loan programs to help small businesses
keep their workers employed and healthcare benefits covered in the group market.
In addition, these legislative reforms and the Internal Revenue Service Notice 2020-23, or IRS Notice 2020-23, issued in 	April 2020 in response to the
COVID-19 pandemic include tax deferrals and other beneficial provisions, including a delay of certain payroll and federal income tax payments, which we expect
to have a positive impact on our 2020 cash flows. For more information on measures we have taken to increase our cash on hand, see “Future Sources and Uses of
Liquidity” in this MD&A.
Regulatory changes have also been enacted, and are likely to continue to be enacted, at the state and federal level in response to the COVID-19 pandemic.
Those changes, which could have a significant impact on health benefits, consumer eligibility for public programs, and our cash flows, include mandated
expansion of premium payment terms including the time period for which claims can be denied for lack of payment, mandates related to prior authorizations and
payment levels to providers, additional consumer enrollment windows, and an increased ability to provide services through telehealth. We
-45-

-- 49 of 72 --

are providing extensions to premium payment terms in certain situations and continue to work closely with state regulators that are mandating or requesting such
relief.
The ACA presented us with new growth opportunities, but also introduced new risks, regulatory challenges and uncertainties, and required changes in the way
products are designed, underwritten, priced, distributed and administered. Changes to our business environment are likely to continue as elected officials at the
national and state levels continue to enact, and both elected officials and candidates for election continue to propose, significant modifications to existing laws and
regulations, including changes to taxes and fees. In addition, the legal challenges regarding the ACA, including the 2018 ACA Decision, which judgment has been
stayed pending appeal, continue to contribute to this uncertainty. In a separate development, in April 2020, the U.S. Supreme Court ruled that the federal
government is required to pay health insurance companies for amounts owed, as calculated under the risk corridor program of the ACA. In June 2020, the U.S.
Court of Federal Claims entered a final judgment stipulating that we are entitled to reimbursement for risk corridor amounts from 2014, 2015 and 2016. We will
review developments and recognize the impact, if any, in a future reporting period. We will continue to evaluate the impact of the ACA as any further
developments or judicial rulings occur.
The annual HIP Fee is allocated to health insurers based on the ratio of the amount of an insurer’s net premium revenues written during the preceding calendar
year to the amount of health insurance premium for all U.S. health risk for those certain lines of business written during the preceding calendar year. We record our
estimated liability for the HIP Fee in full at the beginning of the year with a corresponding deferred asset that is amortized on a straight-line basis to selling,
general and administrative expense. The final calculation and payment of the annual HIP Fee is due by September 30th 	of each fee year. The HIP Fee is non-
deductible for federal income tax purposes. Our affected products are priced to cover the increased selling, general and administrative and income tax expenses
associated with the HIP Fee. The total amount due from allocations to all health insurers is 	$15,523 	for 2020. For the 	three and six 	months ended 	June 30, 2020, we
estimated our portion of the HIP Fee to be 	$420 	and 	$837, respectively, which were recognized as general and administrative expense. There was no corresponding
expense for 2019 due to the suspension of the HIP Fee for 2019.
For additional discussion regarding regulatory trends and uncertainties and risk factors, see Part I, Item 1, “Business - Regulation”, Part I, Item 1A, “Risk
Factors”, and the “Regulatory Trends and Uncertainties” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of
Operations” included in our 2019 Annual Report on Form 10-K and Part II, Item 1A, “Risk Factors” included in our Quarterly Report on Form 10-Q for the quarter
ended March 31, 2020.
Other Significant Items
On February 28, 2020, we completed our acquisition of Beacon Health Options, Inc., or Beacon, the largest independently held behavioral health organization
in the country. At the time of acquisition, Beacon served more than thirty-four million individuals across all fifty states. This acquisition aligns with our strategy to
diversify into health services and deliver both integrated solutions and care delivery models that personalize care for people with complex and chronic conditions.
For additional information, see Note 3, “Business Acquisitions,” of the Notes to Consolidated Financial Statements included in Part 1, Item 1 of this Form 10-Q.
In January 2019, we exercised our contractual right to terminate the ESI PBM Agreement, and we completed the transition of our members from Express
Scripts to IngenioRx on January 1, 2020. Notwithstanding our termination of the ESI PBM Agreement, the litigation between us and Express Scripts regarding the
ESI PBM Agreement continues. For additional information regarding this lawsuit, see Note 11, “Commitments and Contingencies - 	Litigation and Regulatory
Proceedings - Express Scripts, Inc. Pharmacy Benefit Management Litigation,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this
Form 10-Q.
In May 2017, we announced that we were terminating the Agreement and Plan of Merger, or Cigna Merger Agreement, between us and Cigna Corporation.
For additional information about ongoing litigation related to the Cigna Merger Agreement, see Note 11, “Commitments and Contingencies - 	Litigation and
Regulatory Proceedings - Cigna Corporation Merger Litigation,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-46-

-- 50 of 72 --

Selected Operating Performance
For the twelve months ended 	June 30, 2020, total medical membership 	increased 	1.6, or 	3.9%. Our medical membership grew in both our Government
Business and Commercial & Specialty Business segments. The increase in medical membership in our Government Business segment was primarily due to fully-
insured membership growth in our Medicaid and Medicare businesses. The increase in medical membership in our Commercial & Specialty Business segment was
primarily driven by growth in our self-funded business, partially offset by declines in our fully-insured membership.
Operating revenue for the 	three months ended June 30, 2020 	was 	$29,178, 	an increase 	of 	$4,001, or 	15.9%, from the 	three months ended June 30, 2019.
Operating revenue for the 	six months ended June 30, 2020 	was 	$58,626, 	an increase 	of 	$9,061, or 	18.3%, from the 	six months ended June 30, 2019. The 	increase 	in
operating revenue for the three and 	six months ended June 30, 2020 	compared to 2019 was primarily driven by pharmacy product revenue related to the launch of
IngenioRx, as well as higher premium revenue in our Government Business segment.
Net income for the 	three months ended June 30, 2020 	was 	$2,276, 	an increase 	of 	$1,137, or 	99.8%, from the 	three months ended June 30, 2019. Net income
for the 	six months ended June 30, 2020 	was 	$3,799, 	an increase 	of 	$1,109, or 	41.2%, from the 	six months ended June 30, 2019. The 	increase 	in net income for the
three and six 	months ended 	June 30, 2020 	compared to 2019 was due to higher operating results in all of our segments. The increase was partially offset by higher
income tax expense and lower net investment income.
Our diluted earnings per share, or EPS, was 	$8.91 	for the 	three months ended June 30, 2020, which represented a 	104.4% 	increase 	from EPS of 	$4.36 	for the
three months ended June 30, 2019. Our fully-diluted EPS was 	$14.85 	for the 	six months ended June 30, 2020, which represented a 	44.5% 	increase 	from fully-
diluted EPS of 	$10.28 	for the 	six months ended June 30, 2019. The 	increase 	in EPS for the 	three and six 	months ended 	June 30, 2020 	compared to 2019 resulted
primarily from the increase in net income.
Operating cash flow for the 	six months ended June 30, 2020 	and 	2019 	was 	$8,025 	and 	$3,067, respectively. This 	increase 	was 	primarily attributable to higher
net income in 2020, a delay of our estimated federal income and certain payroll tax payments as permitted by the CARES Act and IRS Notice 2020-23, and higher
premium receipts as a result of the HIP Fee reinstatement for 2020.
-47-

-- 51 of 72 --

Membership
The following table presents our medical membership by customer type, funding arrangement and reportable segment as of 	June 30, 2020 	and 	2019. Also
included below is other membership by product. At this time, the following table does not include membership resulting from our acquisition of Beacon. The
medical membership and other membership data presented are unaudited and in certain instances include estimates of the number of members represented by each
contract at the end of the period. 	For a more detailed description of our medical membership, see the “Membership” section of Part II, Item 7, “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” included in our 	2019 	Annual Report on Form 10-K.
June 30
(In thousands) 	2020 	2019 	Change 	% Change
Medical Membership
Customer Type
Local Group 	15,616 	15,670 	(54) 	(0.3)%
Individual 	711 	741 	(30) 	(4.0)%
National:
National Accounts 	7,872 	7,693 	179 	2.3 	%
BlueCard® 	6,171 	6,009 	162 	2.7 	%
Total National 	14,043 	13,702 	341 	2.5 	%
Medicare:
Medicare Advantage 	1,366 	1,170 	196 	16.8 	%
Medicare Supplement 	921 	877 	44 	5.0 	%
Total Medicare 	2,287 	2,047 	240 	11.7 	%
Medicaid 	8,180 	7,099 	1,081 	15.2 	%
Federal Employees Health Benefits 	1,616 	1,593 	23 	1.4 	%
Total Medical Membership by Customer Type 	42,453 	40,852 	1,601 	3.9 	%
Funding Arrangement
Self-Funded 	25,888 	25,433 	455 	1.8 	%
Fully-Insured 	16,565 	15,419 	1,146 	7.4 	%
Total Medical Membership by Funding Arrangement 	42,453 	40,852 	1,601 	3.9 	%
Reportable Segment
Commercial & Specialty Business 	30,370 	30,113 	257 	0.9 	%
Government Business 	12,083 	10,739 	1,344 	12.5 	%
Total Medical Membership by Reportable Segment 	42,453 	40,852 	1,601 	3.9 	%
Other Membership
Life and Disability Members 	5,110 	4,906 	204 	4.2 	%
Dental Members 	6,096 	5,931 	165 	2.8 	%
Dental Administration Members 	1,318 	5,523 	(4,205) 	(76.1)%
Vision Members 	7,457 	7,161 	296 	4.1 	%
Medicare Part D Standalone Members 	392 	287 	105 	36.6 	%
-48-

-- 52 of 72 --

Medical Membership
Total medical membership grew in both our Government Business and Commercial & Specialty Business segments as well as by funding arrangement. Fully-
insured membership increased primarily due to growth in our Medicaid and Medicare businesses, partially offset by the membership decreases in our fully-insured
Local Group business. Local Group membership decreased due to lapses and in-group change exceeding sales. Self-funded medical membership increased
primarily as a result of membership increases in our National Accounts business resulting from our acquisition of a third-party administrator and sales and
favorable in-group changes exceeding lapses. The increase in self-funded membership was further attributable to higher BlueCard® 	activity at other Blue Cross
Blue Shield Association, or BCBSA, plans whose members reside in or travel to our licensed areas. Medicaid membership 	increased 	primarily due to organic
growth in existing markets due to the temporary suspension of eligibility recertification during the COVID-19 pandemic as well as our acquisition
of Medicaid plans in Missouri and Nebraska. Medicare membership 	increased 	primarily due to higher sales during open enrollment.
Other Membership
Our other membership can be impacted by changes in our medical membership, as our medical members often purchase our other products that are ancillary to
our health business. We have experienced growth in our life and disability and dental memberships primarily due to higher sales in our Local Group business.
Dental administration membership decreased due to the lapse of a large dental administration services contract. Vision membership increased due to higher sales in
our Medicare and Local Group businesses.
-49-

-- 53 of 72 --

Consolidated Results of Operations
Our consolidated summarized results of operations and other financial information for the 	three and six 	months ended 	June 30, 2020 	and 	2019 	are as follows:
Three Months Ended
June 30
Six Months Ended
June 30
Change
Three Months Ended
June 30
Six Months Ended
June 30
2020 vs. 2019 	2020 vs. 2019
2020 	2019 	2020 	2019 	$ 	% 	$ 	%
Total operating revenue 	$ 	29,178 	$ 	25,177 	$ 	58,626 	$ 	49,565 	$ 	4,001 	15.9 	% 	$ 	9,061 	18.3 	%
Net investment income 	57 	285 	311 	495 	(228) 	(80.0)% 	(184) 	(37.2)%
Net realized gains (losses) on financial instruments 	18 	11 	(6) 	89 	7 	63.6 	% 	(95) 	(106.7)%
Impairment recoveries (losses) recognized in income 	11 	(7) 	(46) 	(17) 	18 	(257.1)% 	(29) 	170.6 	%
Total revenues 	29,264 	25,466 	58,885 	50,132 	3,798 	14.9 	% 	8,753 	17.5 	%
Benefit expense 	19,547 	20,368 	41,036 	39,650 	(821) 	(4.0)% 	1,386 	3.5 	%
Cost of products sold 	2,225 	98 	4,209 	98 	2,127 	NM 	4,111 	NM
Selling, general and administrative expense 	4,046 	3,278 	7,827 	6,444 	768 	23.4 	% 	1,383 	21.5 	%
Other expense1 	297 	269 	575 	542 	28 	10.4 	% 	33 	6.1 	%
Total expenses 	26,115 	24,013 	53,647 	46,734 	2,102 	8.8 	% 	6,913 	14.8 	%
Income before income tax expense 	3,149 	1,453 	5,238 	3,398 	1,696 	116.7 	% 	1,840 	54.1 	%
Income tax expense 	873 	314 	1,439 	708 	559 	178.0 	% 	731 	103.2 	%
Net income 	$ 	2,276 	$ 	1,139 	$ 	3,799 	$ 	2,690 	$ 	1,137 	99.8 	% 	$ 	1,109 	41.2 	%
Average diluted shares outstanding 	255.4 	261.0 	255.9 	261.6 	(5.6) 	(2.1)% 	(5.7) 	(2.2)%
Diluted net income per share 	$ 	8.91 	$ 	4.36 	$ 	14.85 	$ 	10.28 	$ 	4.55 	104.4 	% 	$ 	4.57 	44.5 	%
Effective tax rate 	27.7% 	21.6% 	27.5% 	20.8% 	610bp3 	670bp3
Benefit expense ratio2 	77.9% 	86.7% 	81.1% 	85.6% 	(880)bp3 	(450)bp3
Selling, general and administrative expense ratio4 	13.9% 	13.0% 	13.4% 	13.0% 	90bp3 	40bp3
Income before income tax expense as a percentage
of total revenues 	10.8% 	5.7% 	8.9% 	6.8% 	510bp3 	210bp3
Net income as a percentage of total revenues 	7.8% 	4.5% 	6.5% 	5.4% 	330bp3 	110bp3
Certain of the following definitions are also applicable to all other results of operations tables in this discussion:
NM 	Not meaningful.
1 	Includes interest expense, amortization of other intangible assets and loss (gain) on extinguishment of debt.
2 	Benefit expense ratio represents benefit expense as a percentage of premium revenue. Premiums for the 	three months ended June 30, 2020 	and 	2019 	were 	$25,092 	and 	$23,501,
respectively. Premiums for the 	six months ended June 30, 2020 	and 	2019 	were 	$50,609 	and 	$46,344, respectively. Premiums are included in total operating revenue presented above.
3 	bp = basis point; one hundred basis points = 1%.
4 	Selling, general and administrative expense ratio represents selling, general and administrative expense as a percentage of total operating revenue.
Three Months Ended June 30, 2020 	Compared to the 	Three Months Ended June 30, 2019
Total operating revenue increased, resulting from higher product revenue and premiums. Product revenue represents services performed by our IngenioRx
pharmacy benefit manager for unaffiliated PBM customers and includes ingredient costs (net of any rebates or discounts), including co-payments made by or on
behalf of the customer, and administrative fees. Unaffiliated PBM customers include our self-funded groups that contracted with IngenioRx for PBM services and
external customers outside of the health plans we own. The increase in product revenue reflects the completed transition of our unaffiliated PBM customers to
IngenioRx by January 1, 2020, after commencing its operations during the second quarter of 2019. The growth in premium revenue was mainly due to membership
growth in our Government Business segment. The increase in premiums was further attributable to rate increases designed to cover the impact of the HIP Fee
reinstatement for
-50-

-- 54 of 72 --

2020. These increases were partially offset by a decrease in experience-rated premiums in our Federal Health Products & Services, or FHPS, business.
Net investment income decreased primarily due to losses recognized from energy sector private equity funds, for which the reporting may lag by up to three
months due to the availability of financial information. These losses resulted from a decrease in the worldwide demand for energy during the COVID-19 pandemic.
Benefit expense 	decreased 	primarily due to the lower volume of healthcare claims experienced resulting from delays to routine care and elective procedures
during the COVID-19 pandemic. This decrease was partially offset by increased costs as a result of membership growth in our Medicaid and Medicare businesses.
Our benefit expense ratio 	decreased 	primarily due to the impact of the lower volume of healthcare claims experienced resulting from delays to routine care and
elective procedures during the COVID-19 pandemic, and, to a lesser extent, the HIP Fee reinstatement for 2020. These decreases were partially offset by the
impact of premium credits provided in response to the COVID-19 pandemic to our members enrolled in select Individual plans and fully-insured employer
customers.
Cost of products sold reflects the cost of pharmaceuticals dispensed by IngenioRx for our unaffiliated PBM customers. Cost of products sold increased as we
completed the transition of all of our unaffiliated PBM customers to IngenioRx between the second quarter of 2019, when it began its operations, and January 1,
2020.
Selling, general and administrative expense 	increased 	primarily due to the reinstatement of the HIP Fee for 2020, and, to a lesser extent, increased spend to
support growth in our businesses.
Our selling, general and administrative expense ratio increased due to the reinstatement of the HIP Fee for 2020 and increased spend to support growth in our
businesses. These increases were partially offset by the growth in operating revenue.
Our effective income tax rate 	increased 	primarily due to the reinstatement of the non-tax deductible HIP Fee for 2020, which resulted in additional income tax
expense of $88.
Our net income as a percentage of total revenues 	increased 	in 	2020 	as compared to 	2019 	as a result of all factors discussed above.
Six Months Ended June 30, 2020 	Compared to the 	Six Months Ended June 30, 2019
Total operating revenue 	increased, resulting from higher product revenue and premiums. Product revenue increased as we completed the transition of all of
our unaffiliated PBM customers to IngenioRx between the second quarter of 2019, when it began its operations, and January 1, 2020. Higher premiums were
mainly due to membership growth in our Government Business segment. The increase in premiums was further attributable to rate increases and the impact of the
HIP Fee reinstatement for 2020. These increases in premiums were partially offset by membership declines in our Commercial & Specialty Business segment.
Net investment income decreased primarily due to losses from energy sector private equity funds as a result of a decrease in the worldwide demand for energy
during the COVID-19 pandemic.
We recognized net realized losses on financial instruments during the six months ended June 30, 2020 compared to net realized gains on financial instruments
during the six months ended June 30, 2019. This change was primarily due to the changes in the fair values of our investments in equity securities during the six
months ended June 30, 2020.
Benefit expense 	increased 	primarily due to increased costs as a result of growth in our Medicaid and Medicare membership and overall cost trends across our
businesses. These increases were partially offset by the lower volume of healthcare claims experienced resulting from delays to routine care and elective
procedures during the COVID-19 pandemic.
Our benefit expense ratio 	decreased 	primarily due to the impact of the lower volume of healthcare claims experienced resulting from delays to routine care and
elective procedures during the COVID-19 pandemic, and, to a lesser extent, the HIP Fee reinstatement for 2020. These decreases were partially offset by the
impact of premium credits provided in response to the COVID-19 pandemic to our members enrolled in select Individual plans and fully-insured employer
customers.
-51-

-- 55 of 72 --

Cost of products sold increased as we completed the transition of all of our unaffiliated PBM customers to IngenioRx between the second quarter of 2019,
when it began its operations, and January 1, 2020.
Selling, general and administrative expense 	increased 	primarily due to the reinstatement of the HIP Fee for 2020, and, to a lesser extent, increased spend to
support growth in our businesses.
Our selling, general and administrative expense ratio increased due to the reinstatement of the HIP Fee for 2020 and increased spend to support growth in our
businesses. These increases were partially offset by the growth in operating revenue.
Our effective income tax rate 	increased 	primarily due to the reinstatement of the non-tax deductible HIP Fee for 2020, which resulted in additional income tax
expense of $175.
Our net income as a percentage of total revenue 	increased 	in 	2020 	as compared to 	2019 	as a result of all factors discussed above.
Reportable Segments Results of Operations
Our results of operations discussed throughout this MD&A are determined in accordance with U.S. generally accepted accounting principles, or GAAP. We
also calculate operating gain and operating margin to further aid investors in understanding and analyzing our core operating results and comparing them among
periods. We define operating revenue as premium income, product revenue and administrative fees and other revenue. Operating gain is calculated as total
operating revenue less benefit expense, cost of products sold and selling, general and administrative expense. It does not include net investment income, net
realized gains (losses) on financial instruments, impairment recoveries (losses) recognized in income, interest expense, amortization of other intangible assets, loss
(gain) on extinguishment of debt or income taxes, as these items are managed in our corporate shared service environment and are not the responsibility of
operating segment management. Operating margin is calculated as operating gain divided by operating revenue. We use these measures as a basis for evaluating
segment performance, allocating resources, forecasting future operating periods and setting incentive compensation targets. This information is not intended to be
considered in isolation or as a substitute for income before income tax expense, net income or EPS, prepared in accordance with GAAP, and may not be
comparable to similarly titled measures reported by other companies. For a reconciliation of reportable segments’ operating revenue to the amounts of total
revenue included in the consolidated statements of income and a reconciliation of reportable segments’ operating gain to income before income tax expense, see
Note 15, “Segment Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Beginning in 2020, IngenioRx meets the quantitative thresholds for a reportable segment and the results of our operations are now described through four
reportable segments: Commercial & Specialty Business, Government Business, IngenioRx and Other. For additional information, see Note 15, “Segment
Information,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
-52-

-- 56 of 72 --

The following table presents a summary of the reportable segment financial information for the 	three and six 	months ended 	June 30, 2020 	and 	2019:
Three Months Ended
June 30
Six Months Ended
June 30
Change
Three Months Ended
June 30
Six Months Ended
June 30
2020 vs. 2019 	2020 vs. 2019
2020 	2019 	2020 	2019 	$ 	% 	$ 	%
Operating Revenue
Commercial & Specialty Business 	$ 	8,789 	$ 	9,417 	$ 	18,150 	$ 	18,809 	$ 	(628) 	(6.7)% 	$ 	(659) 	(3.5)%
Government Business 	17,242 	15,538 	34,708 	30,464 	1,704 	11.0 	% 	4,244 	13.9 	%
IngenioRx 	5,269 	248 	10,466 	248 	5,021 	NM 	10,218 	NM
Other 	1,452 	546 	2,479 	1,094 	906 	165.9 	% 	1,385 	126.6 	%
Eliminations 	(3,574) 	(572) 	(7,177) 	(1,050) 	(3,002) 	NM 	(6,127) 	NM
Total operating revenue 	$ 	29,178 	$ 	25,177 	$ 	58,626 	$ 	49,565 	$ 	4,001 	15.9 	% 	$ 	9,061 	18.3 	%
Operating Gain (Loss)
Commercial & Specialty Business 	$ 	1,372 	$ 	983 	$ 	2,792 	$ 	2,581 	$ 	389 	39.6 	% 	$ 	211 	8.2 	%
Government Business 	1,618 	480 	2,029 	854 	1,138 	237.1 	% 	1,175 	137.6 	%
IngenioRx 	304 	— 	653 	— 	304 	NM 	653 	NM
Other 	66 	(30) 	80 	(62) 	96 	(320.0)% 	142 	(229.0)%
Operating Margin
Commercial & Specialty Business 	15.6% 	10.4% 	15.4% 	13.7% 	520 	bp 	170 	bp
Government Business 	9.4% 	3.1% 	5.8% 	2.8% 	630 	bp 	300 	bp
IngenioRx 	5.8% 	—% 	6.2% 	— 	NM 	NM
Three Months Ended June 30, 2020 	Compared to the 	Three Months Ended June 30, 2019
Commercial & Specialty Business
Operating revenue 	decreased 	primarily due to fully-insured membership declines and the impact of premium credits provided in response to the COVID-19
pandemic to support our members enrolled in select Individual plans and fully-insured employer customers. The decrease in operating revenue was further
attributable to less favorable adjustments to our estimates for the ACA risk adjustment premium stabilization program and the absence of pharmacy administrative
fee revenue that is now recognized within the IngenioRx segment. These decreases were partially offset by the impact of the HIP Fee reinstatement for 2020.
The increase in operating gain was primarily driven by the lower volume of healthcare claims experienced resulting from delays to routine care and elective
procedures during the COVID-19 pandemic. This increase was partially offset by the impact of premium credits provided in response to the COVID-19 pandemic,
less favorable adjustments to our estimates for the ACA risk adjustment premium stabilization program and the shift of pharmacy administrative fee earnings to
our IngenioRx segment.
Government Business
Operating revenue 	increased 	primarily due to higher premium revenue as a result of organic growth, acquisitions and new expansions in our Medicaid
business and membership growth in our Medicare business. The increase in premium revenue was further attributable to rate increases, including a refinement of
estimates associated with Medicare risk score revenue, and the HIP Fee reinstatement for 2020. These increases in premiums were partially offset by a decrease in
experience rated premiums in our FHPS business.
-53-

-- 57 of 72 --

The increase in operating gain was primarily driven by the lower volume of healthcare claims experienced resulting from delays to routine care and elective
procedures during the COVID-19 pandemic. This increase was partially offset by higher experience-rated refunds and retroactive rate adjustments in our Medicaid
business.
IngenioRx
Operating revenue and operating gain increased as a result of the transition of our existing members to IngenioRx, which commenced its operations during the
second quarter of 2019. Operating revenue represents product revenues from services performed for our fully-insured Anthem health plans and self-funded
customers and external customers outside of the health plans we own. Product revenues and cost of goods sold for fully-insured Anthem health plan customers are
eliminated in consolidation. Operating gain represents operating revenue less cost of products sold and selling, general and administrative expenses.
Other
Operating revenue increased primarily due to our acquisition of Beacon in February 2020 and higher administrative fees and other revenue from services
performed by our Diversified Business Group, or DBG, which is our integrated health services business, in certain markets.
The increase in operating gain was due to growth in value-added services performed by DBG for our other segments.
Six Months Ended June 30, 2020 	Compared to the 	Six Months Ended June 30, 2019
Commercial & Specialty Business
Operating revenue 	decreased 	primarily due to fully-insured membership declines and the impact of premium credits provided in response to the COVID-19
pandemic to our members enrolled in select Individual plans and fully-insured employer customers. The decrease in operating revenue was further attributable to
the absence of pharmacy administrative fee revenue that is now recognized within the IngenioRx segment and less favorable adjustments to our estimates for the
ACA risk adjustment premium stabilization program. These decreases were partially offset by the impact of the HIP Fee reinstatement for 2020.
The increase in operating gain was primarily driven by the lower volume of healthcare claims experienced resulting from delays to routine care and elective
procedures during the COVID-19 pandemic. This increase was partially offset by the impact of premium credits provided in response to the COVID-19 pandemic,
less favorable adjustments to our estimates for the ACA risk adjustment premium stabilization program and the shift of pharmacy administrative fee earnings to
our IngenioRx segment.
Government Business
Operating revenue 	increased 	primarily due to higher premium revenue as a result of membership growth in our Medicare business and organic growth, new
expansions and acquisitions in our Medicaid business. The increase in premium revenue was further attributable to rate increases, including a refinement of
estimates associated with Medicare risk score revenue, and the HIP Fee reinstatement for 2020. These increases in premiums were partially offset by a decrease in
experience rated premiums in our FHPS business.
The increase in operating gain was primarily driven by the lower volume of healthcare claims experienced resulting from delays to routine care and elective
procedures during the COVID-19 pandemic. The increase was partially offset by higher experience-rated refunds and retroactive rate adjustments in our Medicaid
business.
IngenioRx
Operating revenue and operating gain increased as a result of the transition of our existing members to IngenioRx, which commenced its operations during the
second quarter of 2019. Operating revenue represents product revenues from services performed for our fully-insured Anthem health plans and self-funded
customers and external customers outside of the health plans we own. Product revenues and cost of goods sold for fully-insured Anthem health plan customers are
eliminated in
-54-

-- 58 of 72 --

consolidation. Operating gain represents operating revenue less cost of products sold and selling, general and administrative expenses.
Other
Operating revenue increased primarily due to our acquisition of Beacon in February 2020 and higher administrative fees and other revenue from services
performed by DBG in certain markets.
The increase in operating gain was due to growth in value-added services performed by DBG for our other segments.
Critical Accounting Policies and Estimates
We prepare our consolidated financial statements in conformity with GAAP. Application of GAAP requires management to make estimates and assumptions
that affect the amounts reported in our consolidated financial statements and accompanying notes and within this MD&A. We consider our most important
accounting policies that require significant estimates and management judgment to be those policies with respect to liabilities for medical claims payable, income
taxes, goodwill and other intangible assets, investments and retirement benefits. Our accounting policies related to these items are discussed in our 	2019 	Annual
Report on Form 10-K in Note 2, “Basis of Presentation and Significant Accounting Policies,” to our audited consolidated financial statements as of and for the year
ended 	December 31, 2019, as well as in the “Critical Accounting Policies and Estimates” section of Part II, Item 7, “Management’s Discussion and Analysis of
Financial Condition and Results of Operations.” As of 	June 30, 2020, our critical accounting policies and estimates have not changed from those described in our
2019 	Annual Report on Form 10-K, except for the policies related to investments and receivables, which changed as a result of the adoption of a new accounting
pronouncement.
Medical Claims Payable
The most subjective accounting estimate in our consolidated financial statements is our liability for medical claims payable. Our accounting policies related to
medical claims payable are discussed in the references cited above. As of 	June 30, 2020, our critical accounting policies and estimates related to medical claims
payable have not changed from those described in our 	2019 	Annual Report on Form 10-K. For a reconciliation of the beginning and ending balance for medical
claims payable for the 	six months ended 	June 30, 2020 	and 	2019, see Note 9, “Medical Claims Payable,” of the Notes to Consolidated Financial Statements
included in Part I, Item 1 of this Form 10-Q.
The following table provides a summary of the two key assumptions having the most significant impact on our incurred but not paid liability estimates for the
six months ended June 30, 2020 	and 	2019, which are the trend and completion factors. These two key assumptions can be influenced by utilization levels, unit
costs, mix of business, benefit plan designs, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing
patterns, claim submission patterns and operational changes resulting from business combinations.
Favorable Developments by
Changes in Key Assumptions
Six Months Ended
June 30
2020 	2019
Assumed trend factors 	$ 	558 	$ 	311
Assumed completion factors 	142 	103
Total 	$ 	700 	$ 	414
The favorable development recognized in the 	six months ended June 30, 2020 	and 	2019 	resulted primarily from trend factors in late 	2019 	and late 	2018,
respectively, developing more favorably than originally expected. Favorable development in the completion factors resulting from the latter parts of 	2019 	and 	2018
developing faster than expected also contributed to the favorability.
The ratio of current year medical claims paid as a percent of current year net medical claims incurred was 	79.1% 	and 79.4% for the 	six months ended June 30,
2020 	and 	2019, respectively. This ratio serves as an indicator of claims processing
-55-

-- 59 of 72 --

speed whereby claims were processed at a similar speed during the six months ended June 30, 2020 as compared to the six months ended June 30, 2019.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net medical claims payable less prior year redundancies
in the current period in order to demonstrate the development of the prior year reserves. For the 	six months ended June 30, 2020, this metric was 	8.8%, largely
driven by favorable trend factor development at the end of 	2019 	as well as favorable completion factor development from 2019. For the 	six months ended June 30,
2019, this metric was 	6.1%, largely driven by favorable trend factor development at the end of 	2018.
We calculate the percentage of prior year redundancies in the current period as a percent of prior year net incurred medical claims to indicate the percentage of
redundancy included in the preceding year calculation of current year net incurred medical claims. We believe this calculation supports the reasonableness of our
prior year estimate of incurred medical claims and the consistency in our methodology. For the 	six months ended June 30, 2020, this metric was 	0.9%, which was
calculated using the redundancy of 	$700. For the 	six months ended June 30, 2019, the comparable metric was 	0.6%, which was calculated using the redundancy of
$414. We believe these metrics demonstrate an appropriate level of reserve conservatism.
Investments
On January 1, 2020, we adopted Accounting Standards Update No. 2016-13, 	Financial Instruments - Credit Losses (Topic 326): Measurement of Credit
Losses on Financial Instruments, 	or ASU 2016-13. The amendments in ASU 2016-13 replaced the incurred loss model for measuring expected credit losses and
require expected losses on available-for-sale fixed maturity securities to be recognized through an allowance for credit losses rather than as reductions in the
amortized cost of the securities. There were no other changes to our accounting policy for investments, as disclosed in our Annual Report on Form 10-K for the
year ended December 31, 2019. For additional information, see Note 4, “Investments,” of the Notes to Consolidated Financial Statements included in Part I, Item 1
of this Form 10-Q.
The COVID-19 pandemic and efforts to prevent its spread have drastically impacted the global economy, causing market instability. Given the market
volatility, there is a risk that the value of some of our investments may decline or that our investments that have declined may not recover in future periods.
Additional discussion regarding the impact of COVID-19 on our business, cash flows, financial condition and results of operations can be found elsewhere in
this MD&A.
New Accounting Pronouncements
For information regarding new accounting pronouncements that were adopted and new accounting pronouncements that were issued during the 	six months
ended June 30, 2020, see the “Recently Adopted Accounting Guidance” and “Recent Accounting Guidance Not Yet Adopted” sections of Note 2, “Basis of
Presentation and Significant Accounting Policies,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
Liquidity and Capital Resources
Sources and Uses of Capital
Our cash receipts result primarily from premiums, product revenue, administrative fees and other revenue, investment income, proceeds from the sale or
maturity of our investment securities, proceeds from borrowings, and proceeds from the issuance of common stock under our employee stock plans. Cash
disbursements result mainly from claims payments, administrative expenses, taxes, purchases of investment securities, interest expense, payments on borrowings,
acquisitions, capital expenditures, repurchases of our debt securities and common stock and the payment of cash dividends. Cash outflows fluctuate with the
amount and timing of settlement of these transactions. Any future decline in our profitability would likely have an unfavorable impact on our liquidity.
The COVID-19 pandemic and efforts to prevent its spread have drastically impacted the economy, causing market instability and increasing unemployment in
the United States. While the full impact of COVID-19 on our business remains uncertain, it could have a material adverse effect on our claim payments, collection
of our premiums, product or
-56-

-- 60 of 72 --

administrative fee revenues, investments and our ability to access credit. Additional discussion regarding the impact of COVID-19 can be found elsewhere in this
MD&A.
For a more detailed overview of our liquidity and capital resources management, see the “Introduction” section included in the “Liquidity and Capital
Resources” section of Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our 	2019 	Annual
Report on Form 10-K.
For additional information regarding our sources and uses of capital during the 	three and six 	months ended 	June 30, 2020, see Note 5, “Derivative Financial
Instruments,” Note 10, “Debt,” and Note 12, “Capital Stock - 	Use of Capital - Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial
Statements included in Part I, Item 1 of this Form 10-Q.
Liquidity
A summary of our major sources and uses of cash and cash equivalents for the 	six months ended June 30, 2020 	and 	2019 	is as follows:
Six Months Ended
June 30 	2020 vs. 2019
2020 	2019 	Change
Sources of Cash:
Net cash provided by operating activities 	$ 	8,025 	$ 	3,067 	$ 	4,958
Issuances of commercial paper and short- and long-term debt, net of repayments 	1,229 	— 	1,229
Proceeds from issuance of common stock under employee stock plans 	92 	100 	(8)
Other sources of cash, net 	640 	65 	575
Total sources of cash 	9,986 	3,232 	6,754
Uses of Cash:
Purchases of investments, net of proceeds from sales, maturities, calls and redemptions 	(4,575) 	(1,384) 	(3,191)
Purchases of subsidiaries, net of cash acquired 	(1,906) 	— 	(1,906)
Repurchase and retirement of common stock 	(584) 	(752) 	168
Purchases of property and equipment 	(437) 	(455) 	18
Repayments of commercial paper and short- and long-term debt, net of issuances 	— 	(5) 	5
Cash dividends 	(482) 	(412) 	(70)
Other uses of cash, net 	(911) 	(80) 	(831)
Total uses of cash 	(8,895) 	(3,088) 	(5,807)
Net increase in cash and cash equivalents 	$ 	1,091 	$ 	144 	$ 	947
The 	increase 	in cash provided by operating activities was 	primarily attributable to higher net income in 2020, a delay of our estimated federal income and
certain payroll tax payments as permitted by the CARES Act and IRS Notice 2020-23, and higher premium receipts as a result of the HIP Fee reinstatement for
2020.
Other significant changes in sources or uses of cash year-over-year included an increase in net purchases of investments, an increase in cash paid for
acquisitions and an increase in net proceeds from the issuances of commercial paper and short- and long-term debt.
Financial Condition
We maintained a strong financial condition and liquidity position, with consolidated cash, cash equivalents and investments in fixed maturity and equity
securities of 	$32,036 	at 	June 30, 2020. Since 	December 31, 2019, total cash, cash equivalents and investments in fixed maturity and equity securities 	increased 	by
$5,909, primarily due to cash generated from operations and net proceeds from borrowings. These increases were partially offset by cash paid for acquisitions,
common stock repurchases, cash dividends paid to shareholders and purchases of property and equipment.
-57-

-- 61 of 72 --

Many of our subsidiaries are subject to various government regulations that restrict the timing and amount of dividends and other distributions that may be
paid to their respective parent companies. Certain accounting practices prescribed by insurance regulatory authorities, or statutory accounting practices, differ from
GAAP. Changes that occur in statutory accounting practices, if any, could impact our subsidiaries’ future dividend capacity. In addition, we have agreed to certain
undertakings to regulatory authorities, including requirements to maintain certain capital levels in certain of our subsidiaries.
At 	June 30, 2020, we held 	$4,089 	of cash, cash equivalents and investments at the parent company, which are available for general corporate use, including
investment in our businesses, acquisitions, potential future common stock repurchases and dividends to shareholders, repurchases of debt securities and debt and
interest payments.
Debt
Periodically, we access capital markets and issue debt, or Notes, for long-term borrowing purposes, for example, to refinance debt, to finance acquisitions or
for share repurchases. Certain of these Notes may have a call feature that allows us to redeem the Notes at any time at our option and/or a put feature that allows a
Note holder to redeem the Notes upon the occurrence of both a change in control event and a downgrade of the Notes below an investment grade rating. For more
information on our debt, including redemptions and issuances, see Note 10, “Debt,” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of
this Form 10-Q.
We calculate our consolidated debt-to-capital ratio, a non-GAAP measure, from the amounts presented on our consolidated balance sheets included in Part I,
Item 1 of this Form 10-Q. Our debt-to-capital ratio is calculated as total debt divided by total debt plus total shareholders’ equity. Total debt is the sum of short-
term borrowings, current portion of long-term debt, long-term debt, less current portion and lease liabilities. We believe our debt-to-capital ratio assists investors
and rating agencies in measuring our overall leverage and additional borrowing capacity. In addition, our bank covenants include a maximum debt-to-capital ratio
that we cannot and did not exceed. Our debt-to-capital ratio may not be comparable to similarly titled measures reported by other companies. Our consolidated
debt-to-capital ratio was 	39.5% 	as of 	June 30, 2020 	and 	December 31, 2019.
Our senior debt is rated “A” by S&P Global Ratings, “BBB” by Fitch Ratings, Inc., “Baa2” by Moody’s Investor Service, Inc. and “bbb+” by AM Best
Company, Inc. We intend to maintain our senior debt investment grade ratings. If our credit ratings are downgraded, our business, liquidity, financial condition and
results of operations could be adversely impacted by limitations on future borrowings and a potential increase in our borrowing costs.
Future Sources and Uses of Liquidity
The COVID-19 pandemic and efforts to prevent its spread have drastically impacted the global economy and caused increased volatility in the securities and
credit markets. While the full impact of COVID-19 on our business is currently uncertain, it could have a material adverse effect on our financial condition and our
liquidity.
In response to the COVID-19 pandemic, we have taken certain precautionary measures to preserve our liquidity and financial flexibility, including reducing
our discretionary spending and temporarily suspending our share repurchase activity. After careful consideration, we lifted the temporary suspension and resumed
our share repurchase activities in late June 2020. To increase our cash on hand, we also delayed our quarterly estimated federal income tax payments normally due
during the second quarter of 2020 until July 15, 2020, as permitted by IRS Notice 2020-23. We also delayed certain payroll tax payments as permitted by the
CARES Act. We may take additional actions going forward to maximize our liquidity, including increasing our borrowings from existing or new Federal Home
Loan Bank memberships and other available borrowings. We will continue to monitor the market conditions and act in a prudent manner. Additional discussion
regarding the impact of COVID-19 can be found elsewhere in this MD&A.
We have an authorized commercial paper program of up to $3,500, the proceeds of which may be used for general corporate purposes. Should commercial
paper issuance become unavailable, we intend to use a combination of cash on hand and/or our senior revolving credit facilities, which provide for combined credit
up to $3,500, to redeem any outstanding commercial paper upon maturity. While there is no assurance in the current economic environment, we believe the lenders
participating in our senior credit facilities, if market conditions allow, will be willing to provide financing in accordance with their legal obligations.
-58-

-- 62 of 72 --

We have a shelf registration statement on file with the U.S. Securities and Exchange Commission to register an unlimited amount of any combination of debt
or equity securities in one or more offerings. Specific information regarding terms and securities being offered will be provided at the time of an offering. Proceeds
from future offerings are expected to be used for general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of
credit to our subsidiaries and the financing of possible acquisitions or business expansions.
We regularly review the appropriate use of capital, including acquisitions, common stock and debt security repurchases and dividends to shareholders. The
declaration and payment of any dividends or repurchases of our common stock or debt is at the discretion of our Board of Directors and depends upon our financial
condition, results of operations, future liquidity needs, regulatory and capital requirements and other factors deemed relevant by our Board of Directors.
For additional information regarding our sources and uses of capital at 	June 30, 2020, see Note 4, “Investments,” Note 5, “Derivative Financial Instruments,”
Note 10, “Debt,” and Note 12, “Capital Stock - 	Use of Capital - Dividends and Stock Repurchase Program,” of the Notes to Consolidated Financial Statements
included in Part I, Item 1 of this Form 10-Q.
Risk-Based Capital
Our regulated subsidiaries’ states of domicile have statutory risk-based capital, or RBC, requirements for health and other insurance companies and health
maintenance organizations largely based on the National Association of Insurance Commissioners, or NAIC, RBC Model Act. These RBC requirements are
intended to measure capital adequacy, taking into account the risk characteristics of an insurer’s investments and products. The NAIC sets forth the formula for
calculating the RBC requirements, which are designed to take into account asset risks, insurance risks, interest rate risks and other relevant risks with respect to an
individual insurance company’s business. In general, under the RBC Model Act, an insurance company must submit a report of its RBC level to the state insurance
department or insurance commissioner, as appropriate, at the end of each calendar year. Our regulated subsidiaries’ respective RBC levels as of 	December 31,
2019, which was the most recent date for which reporting was required, were in excess of all mandatory RBC requirements. In addition to exceeding the RBC
requirements, we are in compliance with the liquidity and capital requirements for a licensee of the BCBSA and with the tangible net equity requirements
applicable to certain of our California subsidiaries.
For additional information, see Note 21, “Statutory Information,” in our audited consolidated financial statements as of and for the year ended December 31,
2019 	included in our 	2019 	Annual Report on Form 10-K.
Contractual Obligations and Commitments
We believe that funds from future operating cash flows, cash and investments and funds available under our 5-year and 364-day senior revolving credit
facilities and/or from public or private financing sources will be sufficient for future operations and commitments, and for capital acquisitions and other strategic
transactions.
There have been no material changes to our Contractual Obligations and Commitments disclosure in our 	2019 	Annual Report on Form 10-K other than our
entry into a vendor agreement for information technology infrastructure and related management and support services and an increase in our borrowings. For
additional information regarding our estimated contractual obligations and commitments, see Note 5, “Derivative Financial Instruments,” Note 10, “Debt,” and the
“Other Contingencies” and “Contractual Obligations and Commitments” sections of Note 11, “Commitments and Contingencies,” of the Notes to Consolidated
Financial Statements included in Part I, Item 1 of this Form 10-Q.
-59-

-- 63 of 72 --

FORWARD-LOOKING STATEMENTS
This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,”
“will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking
statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans,
objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to
certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from
those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward- looking statements
that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with
the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the
extent otherwise required by federal securities laws, we do not undertake any obligation to republish revised forward-looking statements to reflect events or
circumstances after the date hereof. These risks and uncertainties include, but are not limited to: the impact of large scale medical emergencies, such as public
health epidemics and pandemics, including COVID-19, and catastrophes; trends in healthcare costs and utilization rates; our ability to secure sufficient premium
rates, including regulatory approval for and implementation of such rates; the impact of federal and state regulation, including ongoing changes in the Patient
Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, as amended, or collectively, the ACA, and the ultimate
outcome of legal challenges to the ACA; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment
portfolios; our ability to contract with providers on cost-effective and competitive terms; competitive pressures and our ability to adapt to changes in the industry
and develop and implement strategic growth opportunities; reduced enrollment; unauthorized disclosure of member or employee sensitive or confidential
information, including the impact and outcome of any investigations, inquiries, claims and litigation related thereto; risks and uncertainties regarding Medicare
and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve
improvement in Centers for Medicare and Medicaid Services, or CMS, Star ratings and other quality scores and funding risks with respect to revenue received
from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations,
audits or reviews; the ultimate outcome of litigation between Cigna Corporation and us related to the merger agreement between the parties and the potential for
such litigation to cause us to incur substantial additional costs, including potential settlement and judgment costs; risks and uncertainties related to our pharmacy
benefit management, or PBM, business including non-compliance by any party with the PBM services agreement between us and CaremarkPCS Health, L.L.C.;
medical malpractice or professional liability claims or other risks related to healthcare and PBM services provided by our subsidiaries; general risks associated
with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately
support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of
capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and
other considerations; the potential negative effect from our substantial amount of outstanding indebtedness; a downgrade in our financial strength ratings; the
effects of any negative publicity related to the health benefits industry in general or us in particular; failure to effectively maintain and modernize our information
systems; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; the impact of international laws and regulations; changes
in U.S. tax laws; intense competition to attract and retain employees; and various laws and provisions in our governing documents that may prevent or discourage
takeovers and business combinations.
-60-

-- 64 of 72 --

ITEM 3. 	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
For a discussion of our market risks, refer to Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” included in our 	2019 	Annual Report on
Form 10-K. There have been no material changes to any of these risks since 	December 31, 2019.
ITEM 4. 	CONTROLS AND PROCEDURES
We carried out an evaluation as of 	June 30, 2020, under the supervision and with the participation of our management, including our Chief Executive Officer
and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the
Securities Exchange Act of 1934, as amended, or the Exchange Act. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer
concluded that our disclosure controls and procedures are effective in timely alerting them to material information relating to us (including our consolidated
subsidiaries) required to be disclosed in our reports under the Exchange Act. In addition, based on that evaluation, the Chief Executive Officer and Chief Financial
Officer concluded that our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file
or submit under the Exchange Act is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as
appropriate to allow timely decisions regarding required disclosures.
There have been no changes in our internal control over financial reporting that occurred during the three months ended 	June 30, 2020 	that have materially
affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1. 	LEGAL PROCEEDINGS
For information regarding legal proceedings at 	June 30, 2020, see the “Litigation and Regulatory Proceedings,” and “Other Contingencies” sections of Note
11, “Commitments and Contingencies” of the Notes to Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.
ITEM 1A. 	RISK FACTORS
Except for the additional risk factor set forth in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, there have been no material changes
to the risk factors disclosed in our 	2019 	Annual Report on Form 10-K.
-61-

-- 65 of 72 --

ITEM 2. 	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table presents information related to our repurchases of common stock for the periods indicated:
Period
Total Number
of Shares
Purchased1
Average
Price Paid
per Share
Total Number
of Shares
Purchased
as Part
of Publicly
Announced
Programs2
Approximate
Dollar Value
of Shares
that May Yet
Be Purchased
Under the
Programs
(in millions, except share and per share data)
April 1, 2020 to April 30, 2020 	6,838 	$ 	204.57 	— 	$ 	3,263
May 1, 2020 to May 31, 2020 	2,038 	270.86 	— 	3,263
June 1, 2020 to June 30, 2020 	216,430 	259.31 	212,500 	3,208
225,306 	212,500
1 	Total number of shares purchased includes 12,806 shares delivered to or withheld by us in connection with employee payroll tax withholding upon the
exercise or vesting of stock awards. Stock grants to employees and directors and stock issued for stock option plans and stock purchase plans in the
consolidated statements of shareholders’ equity are shown net of these shares purchased.
2 	Represents the number of shares repurchased through the common stock repurchase program authorized by our Board of Directors, which the Board of
Directors evaluates periodically. During the three months ended 	June 30, 2020, we repurchased 	212,500 	shares at a total cost of $55 under the program,
including the cost of options to purchase shares. The Board of Directors has authorized our common stock repurchase program since 2003. The Board of
Director’s most recent authorized increase to the program was 	$5,000 	on December 7, 2017. No duration has been placed on our common stock repurchase
program, and we reserve the right to discontinue the program at any time.
ITEM 3. 	DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. 	MINE SAFETY DISCLOSURES
None.
ITEM 5. 	OTHER INFORMATION
None.
-62-

-- 66 of 72 --

ITEM 6. 	EXHIBITS
Exhibit
Number 	Exhibit
3.1 	Amended and Restated Articles of Incorporation of the Company, as amended and restated effective May 15, 2019, incorporated by reference
to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on May 15, 2019.
3.2 	Bylaws of the Company, as amended effective April 8, 2020, incorporated by reference to Exhibit 3.1 to the Company’s Current Report on
Form 8-K filed on April 8, 2020.
4.6(k) 	Form of the 2.250% Notes due 2030, incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on May 5,
2020.
4.6(l) 	Form of the 3.125% Notes due 2050, incorporated by reference to Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on May 5,
2020.
4.7 	Upon the request of the U.S. Securities and Exchange Commission, the Company will furnish copies of any other instruments defining the
rights of holders of long-term debt of the Company or its subsidiaries.
31.1 	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
31.2 	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Exchange Act Rules, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
32.1 	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
32.2 	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
101 	The following material from Anthem, Inc.’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, formatted in Inline XBRL
(Inline Extensible Business Reporting Language): (i) the Consolidated Balance Sheets; (ii) the Consolidated Statements of Income; (iii) the
Consolidated Statements of Comprehensive Income; (iv) the Consolidated Statements of Cash Flows; (v) the Consolidated Statements of
Shareholders’ Equity; and (vi) Notes to Consolidated Financial Statements. The instance document does not appear in the Interactive Data
File because its XBRL tags are embedded within the Inline XBRL document.
104 	Cover Page Interactive Data File formatted in Inline XBRL and contained in Exhibit 101.
-63-

-- 67 of 72 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
ANTHEM, INC.
Registrant
Date: July 29, 2020 	By: 	/S/ JOHN 	E. GALLINA
John E. Gallina
Executive Vice President and Chief Financial Officer
(Duly Authorized Officer and Principal Financial Officer)
Date: July 29, 2020 	By: 	/S/ RONALD 	W. PENCZEK
Ronald W. Penczek
Senior Vice President and Chief Accounting Officer
(Principal Accounting Officer)
-64-

-- 68 of 72 --

Exhibit 31.1
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Gail K. Boudreaux, certify that:
1. 	I have reviewed this report on Form 10-Q of Anthem, Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) 	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
b) 	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
c) 	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) 	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most
recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5. 	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a) 	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
July 29, 2020 	/s/ GAIL K. BOUDREAUX
President and Chief Executive Officer

-- 69 of 72 --

Exhibit 31.2
CERTIFICATION PURSUANT TO
RULE 13a-14(a) AND RULE 15d-14(a) OF THE EXCHANGE ACT RULES,
AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John E. Gallina, certify that:
1. 	I have reviewed this report on Form 10-Q of Anthem, Inc.;
2. 	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
3. 	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. 	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) 	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
b) 	designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
c) 	evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) 	disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most
recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant’s internal control over financial reporting; and
5. 	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):
a) 	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) 	any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
July 29, 2020 	/s/ JOHN E. GALLINA
Executive Vice President and
Chief Financial Officer

-- 70 of 72 --

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Anthem, Inc. (the “Company”) on Form 10-Q for the period ended 	June 30, 2020 	as filed with the Securities and
Exchange Commission on the date hereof (the “Report”), I, Gail K. Boudreaux, President and Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ GAIL K. BOUDREAUX
Gail K. Boudreaux
President and Chief Executive Officer
July 29, 2020

-- 71 of 72 --

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Anthem, Inc. (the “Company”) on Form 10-Q for the period ended 	June 30, 2020 	as filed with the Securities and
Exchange Commission on the date hereof (the “Report”), I, John E. Gallina, Executive Vice President and Chief Financial Officer of the Company, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) 	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) 	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ JOHN E. GALLINA
John E. Gallina
Executive Vice President and Chief Financial Officer
July 29, 2020

-- 72 of 72 --